Methods of treating biliary tract cancer using anti-PD-L1 antibody in combination with chemotherapy
Combining an anti-PD-L1 antibody with chemotherapy enhances treatment outcomes for BTC, improving survival and response rates beyond current standards.
Patent Information
- Application Number
- CN202280093686.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-18
- Filing Date
- 2022-10-25
- Publication Date
- 2024-12-03
AI Technical Summary
Current treatments for biliary tract cancer (BTC) are inadequate, with gemcitabine and cisplatin chemotherapy providing a median overall survival of 11.7 months and a 24-month survival rate of approximately 15%, highlighting the need for improved therapeutic options.
Combining an anti-PD-L1 antibody, such as durvalumab, with chemotherapy, particularly gemcitabine and cisplatin, to treat advanced BTC.
This combination significantly improves overall survival, progression-free survival, objective response rate, duration of response, and disease control rate in patients with BTC.
Smart Images

Figure BDA0005043181650000141 
Figure BDA0005043181650000151 
Figure BDA0005043181650000231
Abstract
Description
Technical Field
[0001] The present disclosure relates to methods of treating biliary tract cancer (BTC) using an anti-PD-L1 antibody in combination with chemotherapy. Background Art
[0002] Biliary tract cancer (BTC) is a heterogeneous group of malignancies that includes intrahepatic and extrahepatic bile duct cancer, gallbladder cancer, and ampulla of Vater cancer. It is usually diagnosed at an advanced stage when curative surgery is no longer possible and the prognosis is poor (Valle et al., Lancet 397(10272):428-44, 2021). Despite trials evaluating several targeted therapies including cediranib, erlotinib, cetuximab, panitumumab, ramucirumab, and melectinib (Valle et al., 2015; Lee et al., 2012; Malka et al., 2014; Leone et al., 2016; Valle et al., Lancet Oncol. 22(10):1468-82, 2021), first-line standard treatment for advanced disease, gemcitabine and cisplatin chemotherapy, has remained unchanged over the past decade and is associated with a median overall survival of 11.7 months and an estimated 24-month survival rate of approximately 15% (Valle et al., 2010), highlighting the need for new therapies (Brindley et al., 2021; Boilève et al., 2021).
[0003] To meet the need for improved clinical management methods for BTC, the present disclosure provides methods comprising administering an anti-PD-L1 antibody in combination with chemotherapy, particularly gemcitabine and cisplatin chemotherapy, as a treatment for patients with advanced biliary tract cancer. Summary of the invention
[0004] The present disclosure provides methods of treating biliary tract cancer (BTC) using an anti-PD-L1 antibody in combination with chemotherapy.
[0005] In one aspect, the disclosure herein provides a method for increasing overall survival of a patient with biliary tract cancer (BTC), the method comprising treating the patient with an anti-PD-L1 antibody and chemotherapy.
[0006] In another aspect, the disclosure herein provides a method for extending progression-free survival in a patient with biliary tract cancer (BTC), the method comprising treating the patient with an anti-PD-L1 antibody and chemotherapy.
[0007] In yet another aspect, the disclosure herein provides a method of treating a patient with biliary tract cancer (BTC), the method comprising treating the patient with an anti-PD-L1 antibody and chemotherapy.
[0008] These and other features and advantages of the present disclosure will be more fully understood from the following detailed description and the appended claims.It should be noted that the scope of the claims is defined by the recitation therein rather than by the specific discussion of the features and advantages set forth in this specification. BRIEF DESCRIPTION OF THE DRAWINGS
[0009] Figure 1 CONSORT diagram is shown.
[0010] Figure 2 The TOPAZ-1 study design is shown.
[0011] Figure 3 Dosing schedules for durvalumab or placebo plus gemcitabine / cisplatin are shown.
[0012] Figure 4 Kaplan–Meier curves for overall survival and progression-free survival in the full analysis set are shown. CI denotes confidence interval, Durva+Gem+Cis denotes durvalumab plus gemcitabine and cisplatin, and Placebo+Gem+Cis denotes placebo plus gemcitabine and cisplatin.
[0013] Figure 5 The Epanechnikov kernel smoothed hazard function is shown.
[0014] Figure 6 Forest plots of overall survival and progression-free survival are shown for subgroups of durvalumab versus placebo in the full analysis set. Circle size is proportional to the number of observed events. Race was defined as Asian identification or non-Asian identification of the patient, regardless of geographic location. Rest of world included patients enrolled in Europe, North America, and South America. CI denotes confidence interval, Durva+Gem+Cis denotes durvalumab plus gemcitabine and cisplatin, ECOG=Eastern Cooperative Oncology Group, PD-L1=programmed cell death-ligand 1, Placebo+Gem+Cis denotes placebo plus gemcitabine and cisplatin, and TAP=positive tumor area (proportion of tumor and / or immune cells stained with PD-L1 of any intensity).
[0015] Figure 7 The primary endpoint of overall survival is shown. Overall survival was improved by the addition of durvalumab to gemcitabine and cisplatin. Median overall survival (95% CI) increased from 11.5 to 12.8 months. After 6 months, the difference between the durvalumab plus gemcitabine and cisplatin curve and the placebo plus gemcitabine and cisplatin curve increased; and this difference continued to increase over time. The overall survival difference increased from 6% at 12 months to 10% at 18 months to 15% at 24 months.
[0016] Figure 8Subgroup analyses of overall survival are shown. The benefit of adding durvalumab to gemcitabine and cisplatin was observed in all subgroups.
[0017] Fig. 9 Overall survival in subgroups by PD-L1 expression is shown. A benefit of adding durvalumab to gemcitabine and cisplatin was observed in PD-L1 expression.
[0018] Fig.10 The positive tumor area (TAP) score using the Ventana PD-L1 (SP263) assay is shown. PD-L1 status is tracked on both tumor cells and immune cells, and the TAP score is measured, which takes both tumor and immune cell PD-L1 expression into account. The benefit of adding durvalumab to gemcitabine and cisplatin was observed regardless of PD-L1 expression.
[0019] Fig.11 Results for the secondary endpoint of progression-free survival (PFS) are shown. By adding durvalumab to gemcitabine and cisplatin, median PFS (95% CI) improved from 5.7 months to 7.2 months.
[0020] Fig.12 Results of the secondary endpoints of (A) objective response rate (ORR) and (B) DoR in tumor response for durvalumab + GemCis (durvalumab group) and placebo + GemCis (placebo group) are shown. ORR improved from 18.7% in the placebo group to 26.7% in the durvalumab group. The median duration of response was 1.6 months in the durvalumab group, which was faster than 2.7 months in the placebo group. More patients were still responding after 9 months, 32.6% in the durvalumab group compared to 25.3% in the placebo group, and after 12 months, 26.1% of patients in the durvalumab group were still responding compared to 15.0% in the placebo group. DETAILED DESCRIPTION
[0021] The present disclosure relates to a method for treating a patient with biliary tract cancer (BTC), the method comprising administering to the patient a combination of an anti-PD-L1 antibody and chemotherapy. The disclosed treatment methods can significantly improve the patient's overall survival (OS), progression-free survival (PFS), objective response rate (ORR), duration of response, and / or disease control rate.
[0022] The present disclosure also relates to a combination of an anti-PD-L1 antibody and a platinum-based chemotherapy and / or an antimetabolite-based chemotherapy for use in the treatment of biliary tract cancer. In one embodiment, a combination of an anti-PD-L1 antibody and gemcitabine and / or cisplatin is provided for use in the treatment of biliary tract cancer. In another embodiment, a combination of an anti-PD-L1 antibody and a platinum-based chemotherapy and / or antimetabolite-based chemotherapy is provided for use in the treatment of biliary tract cancer, wherein the treatment significantly improves the patient's overall survival (OS), progression-free survival (PFS), objective response rate (ORR), duration of remission, and / or disease control rate. In another embodiment, a combination of an anti-PD-L1 antibody and gemcitabine and / or cisplatin is provided for use in the treatment of biliary tract cancer, wherein the treatment significantly improves the patient's overall survival (OS), progression-free survival (PFS), objective response rate (ORR), duration of remission, and / or disease control rate. In yet another embodiment, the anti-PD-L1 antibody is durvalumab.
[0023] The present disclosure also relates to the use of a combination of an anti-PD-L1 antibody and a platinum-based chemotherapy and / or an antimetabolite-based chemotherapy in the manufacture of a drug for use in the treatment of biliary tract cancer. In one embodiment, a combination of an anti-PD-L1 antibody and gemcitabine and / or cisplatin is provided for use in the treatment of biliary tract cancer. In another embodiment, a combination of an anti-PD-L1 antibody and a platinum-based chemotherapy and / or antimetabolite-based chemotherapy is provided for use in the manufacture of a drug for use in the treatment of biliary tract cancer, wherein the treatment significantly improves the patient's overall survival (OS), progression-free survival (PFS), objective response rate (ORR), duration of remission, and / or disease control rate. In another embodiment, a combination of an anti-PD-L1 antibody and gemcitabine and / or cisplatin is provided for use in the manufacture of a drug for use in the treatment of biliary tract cancer, wherein the treatment significantly improves the patient's overall survival (OS), progression-free survival (PFS), objective response rate (ORR), duration of remission, and / or disease control rate. In yet another embodiment, the anti-PD-L1 antibody is durvalumab.
[0024] It should be understood that the specific aspects of the disclosure described herein are not limited to the specific embodiments presented and may vary. It should also be understood that the terms used herein are only used for the purpose of describing specific aspects and are not intended to be limiting unless specifically defined herein. In addition, as will be appreciated by the skilled person, the specific embodiments disclosed herein may be combined with other embodiments disclosed herein without limitation.
[0025] Unless otherwise defined, all technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which this disclosure belongs. The following references provide general definitions of multiple terms used in this disclosure for technical personnel: Singleton et al., Dictionary of Microbiology and Molecular Biology [Microbiology and Molecular Biology Dictionary] (2nd Edition 1994); The Cambridge Dictionary of Science and Technology [Cambridge Dictionary of Science and Technology] (Walker, 1988); The Glossary of Genetics [Genetics Vocabulary], 5th Edition, R. Rieger et al. (Editors), Springer Verlag [Springer Press] (1991); and Hale and Marham, The Harper Collins Dictionary of Biology [Harper Collins Biology Dictionary] (1991). Unless otherwise specified, as used herein, the following terms have the following meanings assigned to them.
[0026] In the present disclosure, “comprises, comprising,” “containing,” and “having,” etc. may have the meanings ascribed to them by U.S. patent law and may mean “includes, including,” etc.; “consisting essentially of or consists essentially” also has the meaning ascribed to it by U.S. patent law and is open-ended, allowing existence beyond what is described as long as the basic or novel features described are not altered by existence beyond what is described, but excluding prior art aspects.
[0027] Unless expressly stated or obvious from the context, as used herein, the term "or" is understood to be inclusive. Unless expressly stated or obvious from the context, as used herein, the terms "a / an" and "the" are understood to be singular or plural.
[0028] Unless expressly stated or apparent from the context, the term "about" as used herein is understood to be within the normal tolerance range of the art, such as within 2 standard deviations of the mean. Approximately can be understood to be within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise apparent from the context, all numerical values provided herein are modified by the term about.
[0029] Any composition or method provided herein can be combined with one or more of any other compositions and methods provided herein.
[0030] The ranges provided herein are understood to be shorthand for all values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or subrange from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.
[0031] Provided herein is a method for improving the objective response rate in patients with BTC, the method comprising treating the patients with an anti-PD-L1 antibody and chemotherapy.
[0032] Also provided herein is a method of prolonging progression-free survival in a BTC patient, the method comprising treating the patient with an anti-PD-L1 antibody and chemotherapy.
[0033] Also provided herein is a method of treating a patient with BTC, the method comprising treating the patient with an anti-PD-L1 antibody and chemotherapy.
[0034] As used herein, "biliary tract cancer (BTC)" refers to any gastrointestinal cancer arising from the bile duct (cholangiocarcinoma), gallbladder, or ampulla of Vater (AoV).
[0035] In some embodiments, the biliary tract cancer is unresectable, locally advanced, and / or metastatic.
[0036] As used herein, the term "unresectable" refers to a cancer or tumor that cannot be completely removed by surgery. As used herein, the term "locally advanced" refers to a cancer that has grown beyond the body site where it first appeared but has not spread to other parts of the body (stage 3). As used herein, the term "metastatic" refers to a cancer that has spread from the body site where it first appeared (the primary site) to other parts of the body (stage 4).
[0037] As used herein, "anti-PD-L1 antibody" refers to an antibody or antigen-binding fragment thereof that selectively binds to a PD-L1 polypeptide. Exemplary anti-PD-L1 antibodies are described, for example, in U.S. Patent Nos. 8,779,108 and 9,493,565, which are incorporated herein by reference. In some embodiments, the anti-PD-L1 antibody is durvalumab, avelumab, atezolizumab, or sugemalimab. In other embodiments, the anti-PD-L1 antibody is durvalumab, avelumab, or atezolizumab. In some embodiments, the anti-PD-L1 antibody is durvalumab.
[0038] As used herein, the term "durvalumab" refers to an antibody that selectively binds to PD-L1 and blocks the binding of PD-L1 to PD-1 and CD80 receptors, as disclosed in U.S. Pat. No. 9,493,565 (wherein durvalumab is referred to as "2.14H9OPT"), which is incorporated herein by reference in its entirety. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to complement component C1q and Fcγ receptors responsible for mediating antibody-dependent cell-mediated cytotoxicity (ADCC). Durvalumab can alleviate PD-L1-mediated inhibition of human T cell activation in vitro and inhibit tumor growth in a xenograft model via a T cell-dependent mechanism.
[0039] As generally used herein, the terms "treat, treating, treatment, etc." refer to reducing, ameliorating, or slowing the progression of a disorder or disease and / or symptoms associated with the disorder or disease. It will be understood that treatment of a disorder, disease, or condition does not require complete elimination of the disorder, disease, or condition or symptoms associated therewith, although it cannot be excluded. In specific embodiments related to BTC, "treat, treating, treatment" may refer to achieving any one or combination of primary or secondary clinical endpoints.
[0040] Anti-PD-L1 antibodies can be administered once or twice every three weeks or every four weeks while providing benefit to the patient. In further embodiments, additional subsequent doses are administered to the patient. Subsequent doses may be administered at different time intervals depending on the patient's age, weight, clinical assessment, tumor burden, and / or other factors (including the judgment of the attending physician).
[0041] In some embodiments, multiple doses of the anti-PD-L1 antibody are administered to the patient. In some embodiments, at least three doses, at least four doses, at least five doses, at least six doses, at least seven doses, at least eight doses, at least nine doses, at least ten doses, at least fifteen doses, at least twenty-six doses, or more than at least twenty doses may be administered to the patient. In some embodiments, the anti-PD-L1 antibody is administered within a two-week period, within a three-week period, within a four-week treatment period, within a six-week treatment period, within an eight-week treatment period, within a twelve-week treatment period, within a twenty-four-week treatment period, within a one-year treatment period, or within a treatment period of more than one year.
[0042] In some embodiments, the interval between doses can be every three weeks (Q3W or q3w). In some embodiments, the interval between doses can be every four weeks (Q4W or q4w). In some embodiments, the interval between doses can be every two months.
[0043] In some embodiments, the anti-PD-L1 antibody is administered twice within a 21-day treatment cycle (ie, a three-week period), with the first dose administered on day 1 of the 21-day cycle and the second dose administered on day 8 of the 21-day cycle. In some embodiments, the treatment cycle can be repeated 1, 2, 3, 4, 5, 6, 7, or 8 times. In some embodiments, the anti-PD-L1 antibody is administered after the final treatment cycle is completed.
[0044] In some embodiments, the anti-PD-L1 antibody is administered after completion of treatment with chemotherapy.
[0045] In some embodiments, one or more doses of an anti-PD-L1 antibody are administered to a patient, wherein the dose is a fixed dose of between 1000 mg and 2000 mg. In some embodiments, one or more doses of an anti-PD-L1 antibody are administered to a patient, wherein the dose is a fixed dose of 1500 mg. In some embodiments, one or two doses of 1500 mg of an anti-PD-L1 antibody are administered to a patient every three weeks or every four weeks. In some embodiments, one or more doses of an anti-PD-L1 antibody are administered to a patient, wherein the dose is about 20 mg / kg. In some embodiments, one or more doses of an anti-PD-L1 antibody are administered to a patient, wherein the dose is about 20 mg / kg of an anti-PD-L1 antibody every three weeks or every four weeks.
[0046] The amount of anti-PD-L1 antibody to be administered to a patient may be adjusted and may depend on various parameters, such as the patient's age, weight, clinical assessment, tumor burden, and / or other factors (including the judgment of the attending physician).
[0047] In some embodiments, administration of an anti-PD-L1 antibody according to the methods provided herein is performed by parenteral administration. For example, the anti-PD-L1 antibody can be administered by intravenous infusion or by subcutaneous injection. In some embodiments, administration is performed by intravenous infusion.
[0048] The treatment methods disclosed herein further include chemotherapy. In some embodiments, chemotherapy comprises one or more platinum-based chemotherapeutic agents. In some embodiments, one or more platinum-based chemotherapeutic agents are carboplatin, cisplatin, oxaliplatin, or a combination thereof. In some embodiments, chemotherapy comprises one or more antimetabolite-based chemotherapeutic agents. In some embodiments, one or more antimetabolite-based chemotherapeutic agents are gemcitabine. In some embodiments, chemotherapy comprises one or more platinum-based chemotherapeutic agents in combination with one or more antimetabolite-based chemotherapeutic agents. In some embodiments, chemotherapy comprises cisplatin and gemcitabine. In some embodiments, one or more doses of cisplatin are administered to the patient, wherein the dose is about 25 mg / m 2 In some embodiments, one or more doses of gemcitabine are administered to the patient, wherein the dose is about 1000 mg / m 2 .
[0049] In some embodiments, the anti-PD-L1 antibody is administered concurrently with chemotherapy. In some embodiments, the anti-PD-L1 antibody is administered sequentially with chemotherapy within about three days. In some embodiments, the anti-PD-L1 antibody is administered sequentially with chemotherapy within about two days. In some embodiments, the anti-PD-L1 antibody is administered sequentially with chemotherapy within about one day. In some embodiments, the anti-PD-L1 antibody is administered concurrently with chemotherapy (e.g., administered simultaneously (on the same day)). In some embodiments, the anti-PD-L1 antibody is administered on day 1 of a chemotherapy treatment cycle. In some embodiments, the first dose of the anti-PD-L1 antibody is administered on day 1 of a 21-day treatment cycle with chemotherapy, and the second dose of the anti-PD-L1 antibody is administered on day 8 of a 21-day treatment cycle.
[0050] In some embodiments, the toxicities observed with treatment with an anti-PD-L1 antibody in combination with chemotherapy are similar to toxicities typically seen with chemotherapy or immunotherapy alone.
[0051] In some embodiments, the patient has previously received separate surgery and / or adjuvant therapy and / or chemotherapy for biliary tract cancer. In some embodiments, the patient has not previously been treated for biliary tract cancer. In some embodiments, the patient has previously been treated for biliary tract cancer, and the treatment is not curative. In some embodiments, the patient has previously been treated for biliary tract cancer, and the treatment is curative, but the patient has developed recurrent disease. In some embodiments, the patient has developed recurrent disease more than 2, 3, 4, 5, 6, 7, 8, 9 months or more than 9 months after surgery with a curative tendency. In some embodiments, the patient has developed recurrent disease more than 2, 3, 4, 5, 6, 7, 8, 9 months or more than 9 months after completing adjuvant therapy.
[0052] In some embodiments, the methods of treatment disclosed herein provide an increase in PFS relative to placebo. In some embodiments, these methods provide an increase in ORR relative to placebo. In some embodiments, these methods provide an increase in OS relative to placebo.
[0053] Overall survival (OS) refers to the time period from the date of treatment to the date of death from any cause. OS can refer to overall survival over a period of time (e.g., 12 months, 18 months, 24 months, etc.). Such a time period can be identified, for example, as "OS24," which refers to the number (%) of patients who are alive 24 months after the start of treatment based on the Kaplan-Meier 24-month overall survival estimate.
[0054] Progression-free survival (PFS) refers to the time period from the treatment date to the objective disease progression (RECIST 1.1) or the death date (due to any reason in the absence of progression). In some embodiments, the methods of the present disclosure provide an increase in PFS. In some embodiments, these methods provide at least 9 months to at least about 24 months (e.g., at least 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or more than 24 months, and up to about 5 years) PFS.
[0055] The objective response rate (ORR) was defined as the number of patients (%) with a complete response (CR) or partial response (PR) (according to RECIST 1.1) at least once in the study.
[0056] Duration of response (DoR) was defined as the time from the date of the first documented response to the date of the first documented progression or death in the absence of disease progression (ie, date of PFS event or censoring – date of first response + 1).
[0057] Disease control rate (DCR) was defined as the best objective response rate of CR, PR, or stable disease (SD) according to RECIST 1.1.
[0058] Patient-reported outcomes (PROs) are a type of clinical outcome assessment. PROs are used to assess treatment effectiveness in cancer clinical studies. Quality of life questionnaires are used to assess PRO-related assessments. PROs use direct patient input to identify significant symptom, functional, and health-related quality of life (HRQoL) burdens experienced by patients with advanced BTC. PRO endpoints were measured using the European Organization for Research and Treatment of Cancer (EORTC) 30-item core quality of life questionnaire (QLQ-C30) and the supplementary EORTC-21-item Cholangiocarcinoma and Gallbladder Cancer Quality of Life Questionnaire (QLQ-BIL21), Patient-Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO CTCAE), Patient Global Impression of Severity (PGIS), and EuroQoL 5-Dimension 5-Level Health State Utility Index (EQ-5D-5L). These questionnaires show the overall impact of the benefits and toxicities of treatment from the patient's perspective and help understand the benefit / risk assessment. The EORTC QLQ-C30 and EORTC QLQ-BIL21 assess the impact of treatment and disease status on symptoms, effects, and HRQoL. The EORTC scale includes many key BTC symptoms and effects, such as abdominal pain, fatigue, pruritus, jaundice, loss of appetite, physical function, and insomnia.
[0059] The EORTC QLQ-C30 consists of 30 items and assesses HRQoL / health status through the following 9 multi-item scales: 5 functional scales (i.e., physical, role, cognitive, emotional, and social), 3 symptom scales (i.e., fatigue, pain, and nausea and vomiting), and 1 global health status / QoL scale. Also included are 6 single-item symptom / impact measures: dyspnea, insomnia, loss of appetite, constipation, diarrhea, and financial difficulties.
[0060] The EORTC QLQ-BIL21 is used as an additional supplement to the EORTC QLQ-C30. The EORTC QLQ-BIL21 consists of 21 questions: 3 single-item assessments covering treatment side effects, difficulty with drainage bags / tubes, and concerns about weight loss; in addition, there are 18 items divided into 5 scales, namely pain symptoms (4 items), fatigue symptoms (3 items), jaundice symptoms (3 items), anxiety symptoms (4 items), and eating symptoms (4 items).
[0061] Patient-reported outcomes (PRO)-Common Terminology Criteria for Adverse Events (PRO CTCAE), Patient Global Impression of Severity (PGIS), and EuroQoL 5-dimension 5-level Health State Utility Index (EQ-5D-5L) assessed treatment benefits and risks from the patient's perspective.
[0062] PRO-CTCAE assesses tolerability from the patient's perspective. PRO-CTCAE is a symptom item library. PRO-CTCAE includes six different symptomatic adverse events (AEs).
[0063] The Patient Global Impression of Severity (PGIS) assesses patients' perception of the overall severity of their cancer symptoms over the past 7 days. This is a single-item questionnaire, and patients select from a range of answer options from "no symptoms" to "very severe."
[0064] The EQ-5D-5L is a questionnaire that provides a brief summary of health and a single index value of health status for economic evaluation (EuroQol Group, 2015). The EQ-5D-5L questionnaire includes five questions covering five dimensions of health (i.e., mobility, self-care, daily activities, pain / discomfort, and anxiety / depression). Respondents also rate their health status on the day using the EQ visual analogue scale (VAS), which ranges from 0 (worst health status imaginable) to 100 (best health status imaginable).
[0065] Examples
[0066] Example 1: Efficacy of durvalumab combined with chemotherapy in first-line advanced biliary tract cancer patients (TOPAZ-1)
[0067] Overview
[0068] This is a randomized, double-blind, placebo-controlled, multicenter, global Phase III study that determined the efficacy and safety of first-line treatment with durvalumab in combination with gemcitabine / cisplatin relative to placebo in combination with gemcitabine / cisplatin in patients with previously untreated, unresectable locally advanced or metastatic BTC. Figure 2 An overview of the study design is shown.
[0069] Approximately 672 patients with previously untreated, unresectable locally advanced or metastatic BTC were randomized 1:1 to receive one of the following treatments (approximately 336 patients were randomized to each group):
[0070] Group A: Combination therapy of durvalumab plus gemcitabine / cisplatin. Durvalumab 1500 mg (via intravenous (IV) infusion, q3w, starting from cycle 1) plus 25 mg / m 2 Cisplatin and 1000 mg / m 2Patients were treated with gemcitabine (administered on days 1 and 8, q3w) for up to 8 cycles; then durvalumab 1500 mg as monotherapy (q4w) until clinical progression or radiographic progressive disease (PD) defined by RECIST 1.1, unless unacceptable toxicity occurred, consent was withdrawn, or another discontinuation criterion was met.
[0071] Group B: Placebo plus gemcitabine / cisplatin. Placebo (via IV infusion, q3w, starting from cycle 1) plus 25 mg / m 2 Cisplatin and 1000 mg / m 2 Patients were treated with gemcitabine (administered on days 1 and 8, q3w) for up to 8 cycles; then placebo as monotherapy (q4w) until clinical progression or radiographic PD as defined by RECIST 1.1, unless unacceptable toxicity occurred, consent was withdrawn, or another discontinuation criterion was met.
[0072] The primary objective of the study is to confirm the superiority of group A over group B in overall survival (OS) in first-line advanced BTC patients.
[0073] Randomization will be stratified according to disease status (initial unresectable vs. recurrent) and primary tumor site (intrahepatic vs. extrahepatic cholangiocarcinoma vs. gallbladder cancer).
[0074] Patients will receive 25 mg / m 2 Cisplatin and 1000 mg / m 2 Gemcitabine (administered on days 1 and 8, q3w) plus durvalumab 1500mg (Arm A) or placebo (Arm B) via IV infusion q3w, starting with cycle 1 and continuing for up to 8 cycles. After completion of treatment with gemcitabine / cisplatin, patients will receive durvalumab 1500mg (Arm A) or placebo (Arm B) via IV infusion q4w until clinical progression or radiographic PD defined by RECIST 1.1, unless unacceptable toxicity occurs, consent is withdrawn, or another discontinuation criterion is met ( Figure 3 (It should be noted that if the patient's body weight drops to ≤30 kg, the patient should receive a weight-based dose equivalent to 20 mg / kg durvalumab [or placebo] q3w or q4w after consultation between the investigator and the study physician until the body weight improves to >30 kg, at which time the patient should start receiving a fixed dose of 1500 mg durvalumab [or placebo] q3w or q4w.)
[0075] Goals and End Points
[0076] The primary endpoint of the proposed study will be overall survival (OS), which is defined as the time from the date of randomization to death due to any cause. In this phase III study supported by the US Food and Drug Administration and European Medicines Agency guidelines, OS is considered the most reliable cancer endpoint (US Food and Drug Administration, 2007; European Medicines Agency, 2012). Given that the median overall survival (mOS) of patients with advanced BTC receiving gemcitabine and cisplatin is <1 year, OS is considered the most appropriate endpoint (Valle et al., 2010; Okusaka et al., 2010).
[0077] Secondary efficacy endpoints will include progression-free survival (PFS), objective response rate (ORR), duration of response (DoR), disease control rate (DCR), and patient-reported outcome (PRO) measures. All tumor-related endpoints will be assessed by site investigators according to RECIST 1.1; ORR and DoR will also be assessed by BICR according to RECIST 1.1 for IA-1.
[0078] The study objectives and end points are summarized in Table 1 .
[0079] Table 1. Objectives and endpoints
[0080]
[0081]
[0082] Note: Patients in Group A will receive the combination of durvalumab plus gemcitabine / cisplatin; patients in Group B will receive placebo plus gemcitabine / cisplatin.
[0083] ADA anti-drug antibodies; AE adverse events; BICR blinded independent central review committee; BTC biliary tract cancer; ctDNA circulating tumor deoxyribonucleic acid; DCR disease control rate; DoR duration of response; ECOG Eastern Cooperative Oncology Group; EORTC European Organization for Research and Treatment of Cancer; EQ-5D-5L EuroQoL 5-dimension 5-level health state utility index; HOSAD hospital resource use module; HRQoL health-related quality of life; IA-1 interim analysis 1; MSI microsatellite instability; ORR objective response rate; OS overall survival; PD-L1 programmed cell death ligand-1; PFS progression-free survival; PGIS patient global impression of severity; PK pharmacokinetics; PRO-CTCAE patient-reported outcomes-Common Terminology Criteria for Adverse Events; PS performance status; QLQ-BIL21 21-item quality of life questionnaire for cholangiocarcinoma and gallbladder cancer; QLQ-C30 30-item core quality of life questionnaire; QoL quality of life; RECIST response evaluation criteria in solid tumors; TMB tumor mutation burden; WHO World Health Organization.
[0084] Study Group
[0085] The study population included patients aged ≥18 years with previously untreated, unresectable locally advanced or metastatic BTC (e.g., intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer). AoV cancers have a genetic profile distinct from other BTC subtypes (Yachida et al., 2016). To minimize the diversity of the study population, patients with AoV cancers were excluded from the study.
[0086] Each patient should meet all the inclusion criteria of this study and not meet any exclusion criteria in order to be randomized to receive the study intervention.
[0087] In this protocol, “enrolled” patients are defined as those who signed the informed consent form and received an enrollment number. “Randomized” patients are defined as those who underwent randomization and received a randomization number.
[0088] Patients who did not meet the eligibility requirements were considered screening failures. Prospective approval of protocol deviations (also known as protocol waivers or exemptions) from recruitment and enrollment criteria was not permitted.
[0089] Inclusion Criteria
[0090] Patients were eligible for inclusion in the study only if all of the following inclusion criteria applied and all exclusion criteria did not apply:
[0091] Informed Consent:
[0092] 1. Ability to sign informed consent, including compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and this protocol.
[0093] 2. Provide a signed and dated written ICF prior to any mandatory study-specific procedures, sampling, and analysis.
[0094] 3. Provide signed and dated written informed consent prior to sample collection for optional genetic analysis.
[0095] age
[0096] 4. Age ≥ 18 years at the time of screening. For patients aged < 20 years who were enrolled in Japan, written informed consent should be obtained from the patient and his / her legal representative.
[0097] Patient types and disease characteristics
[0098] 5. Histologically confirmed unresectable advanced or metastatic biliary adenocarcinoma, including (intrahepatic or extrahepatic) cholangiocarcinoma and gallbladder carcinoma.
[0099] 6. Patients will be eligible if they have unresectable or metastatic and previously untreated disease at the time of initial diagnosis.
[0100] 7. Patients who develop recurrent disease >6 months after cure-intending surgery and, if receiving adjuvant therapy (chemotherapy and / or radiation), >6 months after its completion will be eligible.
[0101] 8. At the time of enrollment, the World Health Organization (WHO) / ECOGPS was 0 or 1.
[0102] 9. At least one lesion at baseline meets the criteria of RECIST 1.1 target lesion (TL).
[0103] 10. No prior exposure to immune-mediated therapies, including but not limited to other anti-CTLA 4, anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies, excluding therapeutic anti-cancer vaccines.
[0104] 11. Adequate organ and bone marrow function, defined as follows:
[0105] Hemoglobin ≥9.0 g / dL.
[0106] Absolute neutrophil count ≥1.5×109 / L.
[0107] Platelet count ≥100×109 / L.
[0108] Serum bilirubin ≤ 2.0 × upper limit of normal (ULN); this does not apply to patients with confirmed Gilbert's syndrome. Any clinically significant biliary obstruction should be resolved before randomization.
[0109] Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; for patients with liver metastases, ALT and AST ≤ 5 × ULN.
[0110] · 24-hour urine creatinine clearance (CL) > 50 mL / min, or as calculated by the Cockcroft-Gault formula (using actual body weight):
[0111] ·male
[0112] Creatinine CL (mL / min) = (body weight (kg) × (140 – age)) / (72 × serum creatinine (mg / dL))
[0113] ·female
[0114] Creatinine CL (mL / min) = (body weight (kg) × (140 – age) × 0.85) / (72 × serum creatinine (mg / dL))
[0115] 12. Patients must have a life expectancy of at least 12 weeks at screening.
[0116] weight
[0117] 13. Weight >30kg.
[0118] gender
[0119] 14. Male and / or female.
[0120] other
[0121] Patients must provide a recent tumor biopsy or available unstained archived tumor tissue sample of sufficient quantity to allow analysis (collected ≤ 3 years before screening). The tumor lesion to be biopsied should not be used as the RECIST TL unless no other lesions are suitable for biopsy.
[0122] Patients with HBV infection (characterized by positive hepatitis B surface antigen [HBsAg] and / or anti-hepatitis B core antibody (anti-HBc) with detectable HBV deoxyribonucleic acid (DNA) [≥10 IU / mL or above the detection limit of the local laboratory]) must receive antiviral therapy before randomization according to institutional practice to ensure adequate viral suppression. Patients must continue to receive antiviral therapy during the study and for 6 months after the last dose of study treatment. Patients who test positive for anti-HBc and have undetectable HBV DNA (<10 IU / mL or below the detection limit of the local laboratory) do not require antiviral therapy during treatment unless HBV DNA exceeds 10 IU / mL or reaches the detection limit of the local laboratory. Patients with active coinfection with HBV and HCV (as indicated by positive anti-HCV antibodies) and patients with active coinfection with HBV and hepatitis D virus are not eligible.
[0123] Exclusion criteria
[0124] Medical conditions:
[0125] Ampullary cancer.
[0126] History of allogeneic organ transplantation.
[0127] Active or previously documented autoimmune or inflammatory disease, including inflammatory bowel disease (e.g., colitis or Crohn's disease), diverticulitis (except diverticulosis), systemic lupus erythematosus, sarcoid syndrome, or Wegener syndrome (granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.). The following are exceptions to this criterion:
[0128] Patients with vitiligo or alopecia.
[0129] Patients with hypothyroidism (e.g., following Hashimoto's syndrome) who are stable on hormone replacement therapy.
[0130] Any chronic skin condition not requiring systemic therapy.
[0131] Patients without active disease in the past 5 years were included only after consultation with the study physician.
[0132] Patients with celiac disease that can be managed with diet alone.
[0133] Uncontrolled concurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina, uncontrolled cardiac arrhythmias, active interstitial lung disease (ILD), severe chronic gastrointestinal disorders associated with diarrhea, or psychiatric / social conditions that would limit compliance with study requirements, significantly increase the risk of AEs, or impair the patient's ability to give written informed consent.
[0134] History of other primary malignancies, except the following:
[0135] Patients with malignancy who have received curative-enduring treatment and have no known active disease for ≥5 years prior to receiving the first dose of the investigational product (IP) and are at low potential risk of recurrence.
[0136] Adequately treated non-melanoma skin cancer or lentigo maligna with no evidence of disease.
[0137] Adequately treated carcinoma in situ with no evidence of disease.
[0138] History of leptomeningeal carcinoma.
[0139] History of active primary immunodeficiency.
[0140] Active infection, including tuberculosis (clinical evaluation, including clinical history, physical examination, and radiological findings, and tuberculosis testing consistent with local practice), or human immunodeficiency virus (HIV 1 / 2 antibody positive).
[0141] Any unresolved toxicity from prior anticancer therapy of NCI Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 2, except alopecia, vitiligo, and laboratory values defined in the inclusion criteria.
[0142] Patients with neuropathy ≥ Grade 2 will be evaluated on a case-by-case basis in consultation with the study physician.
[0143] Patients with irreversible toxicity that could not reasonably be expected to be exacerbated by durvalumab treatment were included only after consultation with the study physician.
[0144] Brain metastases or spinal cord compression (including asymptomatic and adequately treated disease). Patients with suspected brain metastases at screening should undergo MRI (preferred) or CT scan, preferably both with IV contrast, prior to study enrollment.
[0145] Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
[0146] Prior / concomitant therapy
[0147] Any concurrent chemotherapy, IP, biological, or hormonal therapy for the treatment of cancer. For non-cancer related conditions, concurrent use of hormonal therapy (eg, hormone replacement therapy) is acceptable.
[0148] No radiation therapy was allowed before the study, including palliative radiation therapy, except in the adjuvant setting.
[0149] Receipt of live attenuated vaccines within 30 days prior to the first dose of IP. It should be noted that patients, if enrolled, should not receive live vaccines while receiving IP and for up to 30 days after receiving the last dose of IP.
[0150] Major surgery (defined by the investigator) within 28 days before the first IP dose. It should be noted that minor surgery for isolated lesions for palliative purposes is acceptable if performed more than 14 days before the first IP dose.
[0151] Patients who have previously received immune-mediated therapy (including but not limited to other anti-PD-1, anti-PD-L1, or anti-CTLA-4).
[0152] Prior local therapy, such as radioembolization.
[0153] Are currently using or have previously used immunosuppressive medications within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:
[0154] Intranasal, inhaled, or topical steroids or local steroid injections (for example, into a joint).
[0155] Systemic corticosteroids in physiologic doses not to exceed 10 mg / day of prednisone or its equivalent.
[0156] Steroids as premedication for hypersensitivity reactions (eg, preoperative CT scan).
[0157] Previous / concurrent clinical research experience
[0158] Participation in another clinical study administering IP within the past 3 months.
[0159] IPs were previously assigned in this study.
[0160] Concurrently enrolled in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
[0161] Prior randomization or treatment in a previous clinical study of durvalumab, regardless of treatment group assignment.
[0162] Other exclusions
[0163] Female patients who are pregnant or breastfeeding; or male / female patients of reproductive potential who are unwilling to use effective birth control from screening to 180 days after the last dose of gemcitabine / cisplatin, or to 90 days after the last dose of durvalumab / placebo monotherapy.
[0164] If the patient is unlikely to comply with the study procedures, restrictions, and requirements, the patient should not participate in the study, at the discretion of the investigator.
[0165] Lifestyle restrictions
[0166] The following restrictions apply to patients during and during the specified time before and after receiving IP:
[0167] Female patients of reproductive potential.
[0168] Female patients of reproductive potential who are not abstinent and plan to have sexual intercourse with intact male partners must use at least 1 highly effective method of contraception from the time of screening, throughout the drug treatment period, and during the drug washout period (180 days after the last dose of gemcitabine / cisplatin, or 90 days after the last dose of durvalumab / placebo monotherapy). Unsterilized male partners of female patients of reproductive potential must use male condoms plus spermicide during this period. Discontinuation of birth control after this time point should be discussed with the responsible physician. Proper abstinence that is consistent with patient preferences and daily lifestyle is acceptable. However, periodic abstinence, rhythm method, and withdrawal are not acceptable methods of contraception. Female patients should avoid breastfeeding during this period.
[0169] Male patients whose female partners are of childbearing potential.
[0170] Non-sterilized male patients who do not abstain from sex and plan to have sexual intercourse with female partners of reproductive potential must use male condoms plus spermicide from screening, throughout the drug treatment period, and during the drug washout period (180 days after the last dose of gemcitabine / cisplatin or 90 days after the last dose of durvalumab / placebo monotherapy). Proper abstinence consistent with patient preference and daily lifestyle is acceptable. However, periodic abstinence, rhythm method, and withdrawal are not acceptable methods of contraception. Male patients should avoid sperm donation during this period.
[0171] Female partners of male patients (of childbearing potential) must also use effective contraceptive methods during this period.
[0172] Of note, women of childbearing potential were defined as those who had not undergone surgical sterilization (ie, bilateral salpingectomy, bilateral oophorectomy, or total hysterectomy) or were postmenopausal.
[0173] A woman is considered postmenopausal if she has not had menstruation for 12 months without another medical reason. The following age-specific requirements apply:
[0174] Women aged <50 years were considered postmenopausal if they had been amenorrhea for ≥12 months after cessation of exogenous hormone therapy and if their luteinizing hormone and follicle-stimulating hormone levels were within the conventional postmenopausal range.
[0175] Women aged ≥50 years were considered postmenopausal if they had amenorrhea for ≥12 months after cessation of all exogenous hormone therapy, had radiation-induced menopause >1 year before their last menstrual period, or had chemotherapy-induced menopause >1 year before their last menstrual period.
[0176] Women who had undergone surgical sterilization (ie, bilateral salpingectomy, bilateral oophorectomy, or total hysterectomy) were eligible.
[0177] Highly effective methods of contraception, defined as methods with a low failure rate (ie, <1% per year) when used consistently and correctly. It should be noted that some methods of contraception are not considered highly effective (eg, male or female condoms with or without spermicide; female diaphragms, diaphragms, or sponges with or without spermicide; non-copper intrauterine devices; progestin-only oral hormonal contraceptives in which ovulation inhibition is not the primary mode of action [excluding Cerazette / desogestrel, which is considered highly effective]; and triphasic combination oral contraceptives).
[0178] Concomitant use of other drugs may alter serum contraceptive hormone levels. Therefore, when prescribing hormonal contraception, it is important to consider drug interactions; there may be a risk of contraceptive failure or other adverse effects.
[0179] For patients receiving gemcitabine / cisplatin (in both groups), local prescribing information regarding contraception, the duration of such prophylaxis, and any other restrictions for these agents should be followed.
[0180] Concomitant therapy
[0181] The investigator must be informed as soon as possible of any medications taken from the time of screening until the end of the clinical treatment phase of the study (including the 90-day follow-up period after the last dose of study drug).
[0182] Any medications or vaccines (including over-the-counter or prescription medications, vitamins, and / or herbal supplements) that the patient is taking at the time of enrollment or receives during the study must be recorded along with the following:
[0183] Reasons for use:
[0184] Date of application, including start date and end date
[0185] Dosage information, including dose, unit, and frequency
[0186] Patients must be instructed not to take any medications, including over-the-counter medicines, without first consulting the investigator.
[0187] Restricted, contraindicated, and permitted concomitant medications are described in the table below. Please also refer to the Dose Modification and Toxicity Management Guidelines. For gemcitabine / cisplatin, please refer to the local prescribing information for warnings, precautions, and contraindications.
[0188] Table 2. Contraindicated concomitant medications
[0189]
[0190]
[0191] Table 3. Supportive drugs
[0192]
[0193]
[0194] NTL non-target lesions.
[0195] Other concomitant treatments
[0196] In addition to the above drugs, the investigator may, at his / her discretion, administer other drugs deemed necessary for the safety and well-being of the patient and record them in the corresponding section of the case report form (CRF).
[0197] Emergency medicine
[0198] Because patients taking durvalumab may experience immune-mediated adverse events (imAEs), steroids and other immunosuppressive rescue medications must be provided to this patient population. 2 products that fall into the immunosuppressant category are infliximab (e.g., for colitis) and mycophenolate mofetil (e.g., for hepatitis). These rescue medications must be received, controlled, and dispensed by an unblinded pharmacist and stored according to the storage conditions on the label, with the unblinded pharmacist reporting temperature fluctuations accordingly. If use is necessary due to an imAE, the IVRS / IWRS will provide the unblinded pharmacist with the kit identification number that was dispensed to the patient at that time. Blinded and unblinded access and notification will be controlled using the IVRS / IWRS.
[0199] Dosage Considerations
[0200] Dose delays were allowed for durvalumab (or placebo) therapy. However, dose reductions for durvalumab (or placebo) therapy were not allowed.
[0201] Investigators should follow local standard clinical practice regarding gemcitabine / cisplatin dose adjustments.
[0202] For gemcitabine / cisplatin, patients may delay and subsequently resume dosing according to local standard clinical practice. If dosing must be delayed for reasons other than treatment-related toxicity, it will be given as soon as possible. If chemotherapy is interrupted for treatment-related toxicity, treatment with durvalumab / placebo may be continued at the investigator's discretion when toxicity resolves to grade 2 or less; in this case, durvalumab / placebo monotherapy will be administered q4w.
[0203] If durvalumab or placebo had to be discontinued due to durvalumab or placebo-related toxicity during the first 8 cycles of durvalumab or placebo combined with gemcitabine / cisplatin, patients were required to complete the treatment discontinuation visit and enter the follow-up period. Continuation of gemcitabine / cisplatin treatment during the follow-up period was at the discretion of the investigator and should be reported as subsequent anticancer treatment in the eCRF. Subsequent anticancer treatment should continue until toxicity resolved to grade 2 or less.
[0204] Treatment interruptions and subject withdrawals
[0205] Study Treatment Interruption
[0206] Individual patients in the study will not receive any further study treatment (durvalumab, placebo, or gemcitabine / cisplatin) if any of the following occur:
[0207] Withdrawal of consent for further IP treatment. Patients may discontinue treatment at any time without precluding further treatment. A patient who discontinues treatment is generally expected to continue participating in the study (e.g., for safety and survival follow-up) unless he / she explicitly withdraws consent for all further participation in any study procedures and assessments.
[0208] Any AE that meets the criteria for discontinuation as defined in the Dose Modification and Toxicity Management Guidelines or as defined in the local prescribing information for gemcitabine / cisplatin. NOTE: Patients who permanently discontinue durvalumab or placebo due to durvalumab / placebo-related toxicity should complete the treatment interruption visit and enter the follow-up period. If this occurs while the patient is receiving SOC (e.g., Cycles 1-8), the investigator may decide at their discretion whether to continue treatment with gemcitabine / cisplatin during the follow-up period as described herein.
[0209] Are pregnant or intend to become pregnant.
[0210] Noncompliance with the study protocol (eg, refusal to attend scheduled visits) in the investigator's opinion led to withdrawal of IP treatment.
[0211] Initiate alternative anticancer therapy, including another investigational agent.
[0212] Efficacy evaluation
[0213] This study will evaluate the primary endpoint of OS. Secondary efficacy endpoints of PFS, ORR, DoR, and DCR will be derived by investigator assessment according to RECIST 1.1; ORR and DoR will also be assessed by BICR according to RECIST 1.1 for IA-1. PRO-related assessments will be assessed using a quality of life questionnaire.
[0214] Baseline RECIST 1.1 assessments (select TL and non-target lesions) should be performed on CT scans (preferred) or MRI scans of the chest, abdomen (including the entire liver and both adrenal glands), and pelvis, preferably all with IV contrast, and should be obtained no more than 28 days before the date of randomization and ideally as close to the date of randomization as possible. Additional anatomical imaging should be performed at baseline and follow-up based on the individual patient's signs and symptoms. It is important to follow the tumor assessment schedule whenever possible. If an unscheduled assessment is performed (e.g., to investigate clinical signs / symptoms of progression), every attempt should be made to perform the subsequent assessment at the next regularly scheduled visit. Follow-up scans collected after a RECIST 1.1-defined radiographic PD should preferably be performed at the next (no later than the next) scheduled imaging visit and no later than 4 weeks after the previous PD assessment; this follow-up scan should be evaluated using the criteria outlined in Appendix A.
[0215] Survival assessment
[0216] For patients who have not yet entered long-term follow-up (i.e., all patients in the Chinese cohort), survival assessments must be performed every 2 months after treatment interruption. Patients who interrupt treatment and are in long-term follow-up (after the first FA DCO) should continue to undergo survival assessments every 3 months during long-term follow-up. Survival information can be obtained by contacting the patient or the patient's family by telephone, or by contacting the patient's current physician. After treatment interruption, detailed information on the first and subsequent cancer therapies will be collected.
[0217] In addition, patients who are on treatment or in survival follow-up will be contacted after DCO for interim, terminal (ie, IA-1, IA-2, and FA), and additional exploratory long-term OS analyses to provide complete survival data. These contacts should generally be performed within 7 days after DCO.
[0218] Clinical outcome assessment
[0219] Clinical outcome assessments are assessments of clinical outcomes through reports by clinicians, patients, or non-clinician observers, or through performance-based assessments (FDA-NIH Biomarker Working Group, 2016). Clinical outcome assessments can be used in clinical research to provide direct or indirect evidence of treatment benefit. PROs are a type of clinical outcome assessment. PRO is an umbrella term that refers to all outcomes and symptoms directly reported by patients. PROs have become very important in assessing the effectiveness of study treatments in clinical research and will help understand benefit / risk assessments (Kluetz et al., 2018). The following PROs will be administered in this study: EORTC-QLQ-C30, EORTC-QLQ-BIL21, PRO-CTCAE, PGIS, and EQ-5D-5L. Each is described below. PROs will be translated into the language of the country in which they are being administered, with the exception of PRO-CTCAE, which will be administered only in the language in which it is available and linguistically validated.
[0220] EORTC QLQ-C30 and EORTC QLQ-BIL21
[0221] The EORTC-QLQ-C30 and EORTC QLQ-BIL21 were selected to assess the impact of treatment and disease status on symptoms, effects, and HRQoL. The EORTC scales include many key BTC symptoms and effects, such as abdominal pain, fatigue, pruritus, jaundice, loss of appetite, physical function, and insomnia.
[0222] The EORTC QLQ-C30 consists of 30 items and assesses HRQoL / health status through the following 9 multi-item scales: 5 functional scales (i.e., physical, role, cognitive, emotional, and social), 3 symptom scales (i.e., fatigue, pain, and nausea and vomiting), and 1 global health status / QoL scale. Also included are 6 single-item symptom / impact measures: dyspnea, insomnia, loss of appetite, constipation, diarrhea, and financial difficulties (Aaronson et al., 1993).
[0223] The EORTC QLQ-BIL21 was developed to measure the QoL of BTC patients and is used as an additional supplement to the EORTC QLQ-C30. The EORTC QLQ-BIL21 consists of 21 questions: 3 single-item assessments covering treatment side effects, drainage bag / tube difficulties, and concerns about weight loss; in addition, there are 18 items divided into 5 scales, namely pain symptoms (4 items), fatigue symptoms (3 items), jaundice symptoms (3 items), anxiety symptoms (4 items), and eating symptoms (4 items).
[0224] The EORTC QLQ-BIL21 has evidence of content validity in BTC patients. It was developed based on a literature review, in-depth interviews with patients, and healthcare provider interviews in a BTC population (Friend et al., 2011). Its measurement properties have also been tested in a BTC population and have strong evidence for internal consistency reliability, test-retest reliability (reproducibility), and construct validity (Kaup-Robberts et al., 2016).
[0225] PRO-CTCAE
[0226] PRO-CTCAE was included to assess tolerability from the patient's perspective. PRO-CTCAE was developed by the National Cancer Institute (NCI). It was developed based on the recognition that collecting treatment-related symptom data directly from patients can improve accuracy and efficiency. It is based on findings from multiple studies that have demonstrated that physicians and nurses underestimate the onset, frequency, and severity of treatment-related symptoms compared to patient ratings (Basch et al., 2009; Litwin et al., 1998; Sprangers and Aaronson, 1992). PRO-CTCAE is a symptom item library, and the items have been extensively qualitatively reviewed by experts and patients. To date, 78 CTCAE symptoms have been identified for patient reporting, but not all items have been applied in any clinical study. Six different symptomatic AEs were selected for PRO-CTCAE based on available safety reports of durvalumab and gemcitabine / cisplatin. In general, symptomatic AEs not included in the EORTC are prioritized for PRO-CTCAE to reduce patient burden in accordance with published recommendations (Trask et al., 2018). PRO-CTCAE will be used only in language versions for which linguistically validated versions exist.
[0227] PGIS
[0228] The PGIS item is included to assess how the patient perceives the overall severity of his / her cancer symptoms over the past 7 days. This is a single-item questionnaire, and the patient will select from answer options ranging from "no symptoms" to "very severe."
[0229] EQ-5D-5L
[0230] Developed by the EuroQoL Group, the EQ-5D-5L is a universal questionnaire that provides a brief health profile and a single index value of health status for economic evaluation (EuroQol Group, 2015). The EQ-5D-5L questionnaire includes five questions covering five dimensions of health (i.e., mobility, self-care, daily activities, pain / discomfort, and anxiety / depression). Respondents also use the EQ visual analogue scale (VAS) to rate their health status on the day, which ranges from 0 (worst health status imaginable) to 100 (best health status imaginable).
[0231] Disease-specific tumor marker samples
[0232] As part of routine safety blood samples, assessments of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA-19-9) will be performed. It is important to follow the assessment schedule as closely as possible. Elevations in CEA or CA-19-9 alone are not sufficient to declare progression and interrupt treatment.
[0233] Progression events should be defined based on radiographic evidence of progression per RECIST 1.1.
[0234] Further evaluation of CEA and CA-19-9 after radiographic progression will be at the discretion of the investigator according to local clinical practice.
[0235] Exploratory genetic testing
[0236] The buffy coat obtained during plasma separation can be retained according to local regulations and analyzed for germline mutations and / or used to identify tumor-specific mutations for microsatellite instability (MSI) / tumor mutation burden (TMB) assessment to more accurately discern tumor-specific mutations.
[0237] Biomarkers
[0238] Tissue samples will be obtained from all screened patients.
[0239] Pretreatment tumor PD-L1 expression will be assessed (retrospectively) in all randomized patients. Data between the two groups will be compared to determine whether baseline PD-L1 status is prognostic and / or predictive of outcomes of interest in Arm A vs Arm B. Baseline tumor requirements are briefly described herein.
[0240] Based on tissue availability, additional exploratory biomarkers can be evaluated as described herein.
[0241] The results can be combined with biomarker data from other durvalumab studies to assess biologic response in various indications and to compare outcomes in monotherapy versus combination settings.
[0242] PD-L1 expression assessment
[0243] The Ventana PD-L1 IHC assay will be used to determine PD-L1 status in tumor samples.
[0244] Exploratory biomarkers
[0245] Blood and tumor samples will be obtained for exploratory biomarker analysis.
[0246] Baseline measurements and / or changes in measurements from baseline in samples during treatment will be associated with outcomes and / or drug treatment. It should be noted that samples will be obtained from patients randomized to each treatment group. Baseline measurements will be compared to determine whether a biomarker (or combination of markers) is prognostic or predictive of an outcome.
[0247] Microsatellite instability (MSI) and tumor mutation burden (TMB)
[0248] Tumor tissue remaining after PD-L1 testing can be retrospectively analyzed for microsatellite instability (MSI) using next-generation sequencing (NGS)-based approaches such as whole exome sequencing (WES) or targeted NGS assays. MSI-H / MSS status and TMB will be determined based on MSI events or somatic variants detected in tumor sequence data and correlated with efficacy as exploratory objectives. Blood-based MSI or TMB testing may also be performed in cases where tissue material is insufficient, tissue-based MSI testing is unsuccessful, or to assess blood-based MSI / TMB with clinical outcomes and other biomarkers. Matched normal DNA obtained from the buffy coat collected during plasmapheresis can be used to identify tumor-specific mutations for MSI / TMB assessment. The inclusion of matched normal DNA in mutation analysis helps to more accurately discern tumor-specific mutations in a heterogeneous tumor cell population, which can also reduce or prevent the inadvertent inclusion of normal inherited germline mutations in the final analysis or study reporting.
[0249] If NGS-based MSI testing is not feasible or fails, MMR testing by IHC or similar methods will be performed.
[0250] Tumor Microenvironment Biomarkers
[0251] Based on tissue availability, a panel of additional immune-related markers expressed in TILs or tumor cells can be assessed using immunohistochemistry (IHC), gene expression profiling, or other technically feasible methods. Markers of particular interest include, but are not limited to, CD8, FOXP3, CD68, CD3, CD73, NKp46, CXCL9, and LAG3.
[0252] Other tissue-based approaches may be used, including but not limited to neoantigen prediction, T cell receptor clonality assessment, molecular profiling, and / or somatic variant detection methods. Note: This analysis is not performed in China.
[0253] Whole blood gene expression (PaxGeneRNA)
[0254] Whole blood samples will be obtained for RNA analysis. Total RNA will be prepared using reverse transcription quantitative polymerase chain reaction, microarray, sequencing, or other techniques for quantification of RNA, microRNA, and / or other noncoding RNA. Emphasis may be placed on the expression of immune regulatory genes. Baseline and / or on-treatment correlation analysis with outcome data will be completed for selected candidate predictive markers with the goal of identifying useful expression thresholds to identify patients who may benefit. These samples may also be used for additional molecular analysis of immune response-related features such as, but not limited to, T cell receptor clonality and HLA typing. NOTE: This sample is not collected in China.
[0255] Soluble factors - plasma
[0256] Blood samples will be collected at multiple time points for analysis of circulating factors, such as circulating tumor deoxyribonucleic acid (ctDNA) in plasma. Analysis may include, but is not limited to, evaluation of baseline sensitizing mutations for treatment and association with clinical outcomes, changes in ctDNA levels and mutation frequencies, and potential minimal residual disease. Relevant cytokines, chemokines, and other soluble biomarkers in plasma may also be evaluated.
[0257] The buffy coat obtained during the plasmapheresis process of the baseline sample can be retained and analyzed according to local regulations. DNA isolated from the buffy coat will be used as a reference for patient-specific normal DNA to determine whether mutations identified in ctDNA or tumor mutation analysis are tumor-specific (somatic). Note: This analysis is not performed in China.
[0258] Serum samples for biomarkers
[0259] Serum is obtained to explore the expression of cytokines and chemokines, including but not limited to IFN-γ, interleukin 18, CXCL9, and CXCL10. Similarly, the concentration of a panel of IC ligands, receptors, or other soluble factors can be assessed. Proteins of particular interest include CTLA-4, PD-1, PD-L1, B7-1, B7-2, and IL6R. In addition, the serum proteome can be explored using mass spectrometry-based or similar techniques. Circulating exosomes can also be isolated from serum to assess exosomal RNA, DNA, and / or protein content. Note: This sample is not collected in China.
[0260] Outcome measures used for analysis
[0261] Statistical methods
[0262] The primary objective of the study was to confirm the superiority of group A over group B in terms of OS in patients with advanced BTC.
[0263] The primary endpoint, OS, was defined as the time from the date of randomization to death from any cause. Secondary efficacy endpoints included progression-free survival (PFS), ORR, duration of response (DoR), disease control rate (DCR), and PRO metrics.
[0264] The Full Analysis Set (FAS) will include all randomized patients. The FAS will be used for all efficacy analyses, including PROs. Treatment groups will be compared based on randomization to study treatment, regardless of actual treatment received. Patients who were randomized but subsequently did not continue to receive study treatment will be included in the analysis of the treatment group to which they were randomized.
[0265] The hypothesis of OS improvement will be tested in the following cases:
[0266] Approximately 397 OS events occurred in Interim Analysis 2 (IA-2) of Arms A and B (59% maturity), and
[0267] Approximately 496 OS events occurred in the final analysis (FA) of groups A and B (74% maturity).
[0268] The primary analysis of OS was based on the log-rank test at the interim analysis and the Fleming-Harrington (FH)(0,1) test at the final analysis. A sensitivity analysis using the log-rank test will also be performed at the final analysis. If the true mean OS hazard ratio (HR) is 0.745, approximately 496 OS events will provide 90% power to demonstrate statistical significance at the 4.20% level (using a two-sided log-rank test), allowing 1 interim analysis of clinical activity assessed by ORR and DoR and 1 interim analysis of early superiority testing for OS improvement of approximately 80% of target events. Using the log-rank test, the minimum treatment difference that was statistically significant at the time of FA was a mean HR of 0.833. Assuming a recruitment period of 21 months and a minimum follow-up of 19 months, this analysis is expected to be performed approximately 40 months after the first patient is randomized. The overall power of at least 86% for the second interim analysis with the log-rank test and the final analysis with FH(0,1) was considered in all scenarios.
[0269] Two interim analyses and one FA are planned to assess efficacy:
[0270] IA-1: The goal of IA-1 is to evaluate clinical activity. ORR and DoR will be summarized to support early enrollment of durvalumab when durvalumab is administered in combination with gemcitabine / cisplatin. Investigator assessments and blinded independent central review committee (BICR) assessments will be summarized according to RECIST 1.1. The planned data cutoff (DCO) of IA-1 will occur when at least 200 patients have had the opportunity to be followed for at least 32 weeks, or the last patient is randomized to the global cohort, whichever is later. The analysis set will include all randomized patients who have the opportunity to have at least 32 weeks of follow-up at the time of IA-1 DCO (i.e., randomized ≥32 weeks prior to IA-1 DCO).
[0271] Based on the enrollment assumptions, this is expected to occur approximately 21 months after the first patient is randomized.
[0272] IA-2: The second interim analysis will test the early superiority of the durvalumab regimen over the control. This analysis will be performed when approximately 397 OS events have been observed in the study (59% maturity or 80% log-rank test informative portion) and power is 75%. Based on the enrollment assumptions, this is expected to occur approximately 31 months after the first patient is randomized.
[0273] IA-2 will evaluate the efficacy of Arm A compared to Arm B in terms of OS (primary objective). OS will be analyzed using a stratified log-rank test (stratified by disease status and primary tumor location). Treatment effects will be estimated by HR, 95% confidence interval (CI), and p-value.
[0274] A small alpha expenditure of 0.001 (0.1%) will be allocated to IA-1. Tight control of the family-wise error rate (FWER) to the remaining 4.9% level (two-sided) throughout testing of the OS and PFS endpoints will be achieved by a combined approach of alpha assignment (IA-2 and FA) to the OS analysis via an alpha spending function and hierarchical testing procedure; that is, PFS will be tested only if OS reaches statistical significance in IA-2 or FA (Glimm et al., 2010). IA-2 for OS will be performed when approximately 397 of the 496 expected OS events (i.e., for the 80% information portion of the log-rank test) have occurred. Using the Lan-DeMets spending function that approximates the O'Brien-Fleming boundary, two-sided significance levels of 0.0238 and 0.0420 will be applied to OS IA-2 and FA, respectively, using the log-rank test (Lan and DeMets, 1983). The significance level of the FH(0,1) test in the final analysis will be determined based on the association between the interim and final data (Tsiatis, 1982).
[0275] If OS meets statistical significance for DCO (IA-2 or FA), PFS will be formally tested using PFS information collected prior to each DCO. The PFS significance levels for IA-2 and FA will be derived based on an alpha-spending function that approximates the Pocock bound, which tightly controls the type I error at the 0.049 level (two-sided). Assuming that approximately 506 PFS events and 590 PFS events are available at the time of each PFS analysis, PFS testing will be performed based on a two-sided significance level of 0.0444 and 0.0236 in IA-2 and FA, respectively, based on the log-rank test. Because DCO timing will be determined based on the number of OS events, the nominal significance level of the PFS analysis may be adjusted based on the actual portion of PFS information from IA-2 relative to FA.
[0276] Safety data will be summarized descriptively but will not be formally analyzed.
[0277] Additional exploratory overall survival analyses will be performed using long-term follow-up survival data, which can be collected up to approximately 4 years after the last randomization of patients in the global cohort.
[0278] Populations used for analysis
[0279] Definitions of the analysis sets for each outcome variable are provided in Table 4 .
[0280] Table 4. Summary of outcome variables and analysis populations
[0281]
[0282] AE adverse events; DoR duration of response; ORR objective response rate; OS overall survival; PFS progression-free survival; PK pharmacokinetics; PRO patient-reported outcomes.
[0283] Full analysis set
[0284] The FAS will include all randomized patients. The FAS will be used for all efficacy analyses, including PROs. Treatment groups will be compared based on randomization to study treatment, regardless of the actual treatment received. Patients who were randomized but subsequently did not continue to receive study treatment will be included in the analysis of the treatment group to which they were randomized.
[0285] The analysis of ORR will be based on patients with baseline measurable disease in the FAS. The analysis of DoR will be based on patients who achieved an objective response in the FAS.
[0286] Security Analysis Set
[0287] The SAS will consist of all patients who received at least 1 dose of study treatment. Safety data will not be formally analyzed but will be summarized descriptively using the SAS according to treatment received; that is, patients who were incorrectly treated (e.g., patients who were randomized to treatment A but were given treatment B) will be summarized according to the treatment they actually received.
[0288] Pharmacokinetic Analysis Set
[0289] All patients who received at least 1 dose of durvalumab per protocol will be included in the PK analysis set if any post-dose data are available and there are no protocol violations or deviations in a manner that significantly affects the PK analysis. The population will be defined by the study physician, pharmacokinetist, and statistician prior to any analysis.
[0290] ADA analysis set
[0291] The ADA analysis set will include all subjects with non-missing baseline ADA and at least 1 non-missing post-baseline ADA result. All primary ADA analyses will be based on the ADA analysis set.
[0292] Safety Assessment
[0293] For summaries of changes from baseline in vital signs, laboratory data, ECGs, and physical examinations, the baseline value will be the most recent result obtained before the start of study treatment.
[0294] QTcF will be derived during the creation of the reporting database using the reported ECG values (RR and QT) using the following formula:
[0295] QTcF=QT / RR 1 / 3, where RR is in seconds
[0296] The corrected calcium product will be derived during creation of the reporting database using the following formula:
[0297] Corrected calcium (mmol / L) = total calcium (mmol / L) + ([40 – albumin (G / L)] × 0.02)
[0298] The denominator used in the laboratory summary will include only evaluable patients, that is, patients with sufficient data to demonstrate a possible abnormality.
[0299] For example:
[0300] If the CTCAE criteria involved a change from baseline, evaluable patients would have a pre-dose value and at least 1 post-dose value recorded.
[0301] If the change from baseline was not considered evaluable by CTCAE criteria, patients were only required to record 1 post-dose value.
[0302] Denominators in vital signs data should include only patients for whom data were recorded.
[0303] Calculation or derivation of patient-reported outcome variables
[0304] EORTC QLQ-C30
[0305] The EORTC QLQ-C30 consists of 30 questions that can be combined into 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea / vomiting), and an overall health status / QoL scale. The EORTC QLQ-C30 will be scored according to the EORTC QLQ-C30 scoring manual (Fayers et al., 2001). According to the EORTC QLQ-C30 scoring manual, outcome variables consisting of scores from 0 to 100 for each symptom scale, each functional scale, and the overall health status measure scale in the EORTC QLQ-C30 will be derived. Higher scores on the overall health status measure and functional scale indicate better health status / functioning, but higher scores on the symptom scale indicate greater symptom severity. In each subscale, if <50% of the subscale items are missing, the subscale score will be divided by the number of non-missing items and multiplied by the total number of subscale items (Fayers et al., 2001). A subscale will be considered missing if at least 50% of the items are missing. A single missing item will be considered missing. The reason for missingness on any questionnaire will be determined and recorded.
[0306] Definition of Clinically Important Changes—Visit Remission and Best Overall Remission
[0307] The overall health status / QoL scale includes 2 items of the EORTC QLQ-C30: "How would you rate your overall health status in the past week?" (Item 29) and "How would you rate your overall QoL in the past week?" (Item 30). The definition of clinically significant changes in scores compared to baseline will be assessed. A clinically significant change is defined as an absolute change of ≥10 in the score of the scale from the EORTCQLQ-C30 relative to baseline (Osoba et al., 1998). For example, a clinically significant improvement in physiological function (as assessed by the EORTC QLQ-C30) is defined as an increase of ≥10 in the score relative to baseline, while a clinically significant deterioration is defined as a decrease of ≥10 in the score relative to baseline. At each post-baseline assessment, changes in overall health status / QoL, symptom and function scores relative to baseline will be classified as improved, unchanged or worsened, as shown in Table 5.
[0308] Table 5. Mean change and clinically important change—EORTC QLQ-C30
[0309]
[0310] Based on the evaluable PRO data collected during the study, the patient's best overall response in terms of symptoms, function, or overall health status / QoL will be derived, i.e., the best response achieved by the patient. The criteria in Table 6 will be used to designate the best response in terms of symptoms, function, or overall health status / QoL.
[0311] Table 6. EORTC QLQ-C30 and EORTC QLQ-BIL21 Best Response Score: FAS
[0312]
[0313]
[0314] EORTC European Organisation for Research and Treatment of Cancer; FAS full analysis set; PRO patient-reported outcomes; QLQ-C30 30-item core quality of life questionnaire; QLQ-BIL21 21-item quality of life questionnaire for cholangiocarcinoma and gallbladder cancer.
[0315] Time to deterioration in HRQoL or function
[0316] Time to worsening of QoL or function will be defined as the time from the date of randomization until the date of the first clinically significant worsening confirmed at a subsequent visit (unless this was the patient's last available assessment), or until the date of death (from any cause) in the absence of a clinically significant worsening, regardless of whether the patient discontinued study treatment or received another anticancer therapy before worsening of global health status / QoL or function. Death will be counted as an event only if it occurs within 2 PRO assessment visits after the last available PRO assessment. Sensitivity analyses will be performed in which deaths will be censored on the day of death.
[0317] If patients did not show clinically meaningful deterioration in their global health status / QoL or function (as measured by the EORTC QLQ-C30) and were still alive at the time of analysis, these patients were censored at their last PRO assessment, at which time global health status / QoL or function could be assessed. In addition, if global health status / QoL or function deteriorated, or if patients died after being lost to follow-up for 2 or more PRO assessments, these patients were censored at the last PRO assessment, at which time global health status / QoL or function could be assessed before the 2 losses to follow-up.
[0318] The population used for analysis of overall health status / QoL or time to functional deterioration will include the subset of FAS with a baseline score ≥10.
[0319] Symptom improvement rate
[0320] Symptom relief (improved, worsened, and unchanged) and best overall relief at each visit will be presented by treatment group based on Table 6. Symptom improvement rate will be defined as the number of patients (%) whose best overall symptom score relief was "improved".
[0321] The denominator will consist of the FAS subset with a baseline symptom score ≥10.
[0322] Overall health status / QoL or functional improvement rate
[0323] The rate of improvement in global health status / QoL or function will be defined as the number (%) of patients whose best global response in QoL or function is "improved".
[0324] The denominator will consist of the FAS subset with a baseline global health status / QoL or functional score ≤90.
[0325] EORTC QLQ-BIL21
[0326] QLQ-BIL21 is a BTC-specific module of the EORTC. This module includes 21 questions to assess BTC symptoms. This module includes 5 multi-domain scales and 3 single-item scales. For all items and scales, high scores indicate increased symptoms / more problems.
[0327] The scoring method of QLQ-BIL21 is in principle the same as the scoring method of the symptom scale / single item of EORTC QLQ-C30. Similar to the symptom scale of EORTC QLQ-C30, higher scores indicate greater symptom severity.
[0328] Definition of Clinically Important Changes—Visit Remission and Best Overall Remission
[0329] Changes in scores from baseline will be assessed. A clinically significant change is defined as an absolute change of ≥10 in the score of a scale / item from QLQ-BIL21 relative to baseline. For example, a clinically significant worsening or aggravation of pain (as assessed by QLQ-BIL21) is defined as an increase of ≥10 in the score relative to baseline. At each post-baseline assessment, changes in symptom scores relative to baseline will be classified as improved, unchanged, or worsened, as shown in Table 7. Based on the evaluable PRO data collected during the study, the patient's best overall relief in terms of symptoms will be derived, i.e., the best relief achieved by the patient. The criteria in Table 6 will be used to specify the best relief of symptom scores.
[0330] Table 7. Mean changes and clinically important changes—EORTC QLQ-BIL21
[0331]
[0332] EORTC European Organisation for Research and Treatment of Cancer; QLQ-BIL21 21-item quality of life questionnaire for bile duct and gallbladder cancer.
[0333] When symptoms worsen
[0334] For each symptom scale / item in the QLQ-BIL21, time to symptom worsening will be defined as the time from randomization until the first clinically significant symptom worsening confirmed at a subsequent visit (unless this was the patient's last available assessment), or until death (from any cause) in the absence of clinically significant symptom worsening, regardless of whether the patient discontinued study treatment or received another anticancer therapy before symptom worsening. Death will be counted as an event only if it occurs within 2 PRO assessment visits after the last available PRO assessment. Sensitivity analyses will be performed in which deaths will be censored on the day of death.
[0335] If patients did not show clinically meaningful worsening of symptoms (as measured by the QLQ-BIL21) and were still alive at the time of analysis, they were censored at their last PRO assessment, at which time symptoms could be assessed. In addition, if symptoms progressed or patients died after being lost to follow-up for 2 or more PRO assessments, they were censored at their last PRO assessment, at which time symptoms could be assessed before the 2 losses.
[0336] The population used for analysis of time to symptom exacerbation will include the subset of FAS with baseline scores ≤90.
[0337] EQ-5D-5L
[0338] The EQ-5D-5L questionnaire consists of 6 questions covering 5 dimensions of health (e.g., mobility, self-care, usual activities, pain / discomfort, and anxiety / depression) and VAS. For each dimension, respondents select the statement that best describes their health status on that day from 5 possible options with increasing severity levels (e.g., no problems, slight problems, moderate problems, severe problems, and unresolvable / extreme problems).
[0339] A unique EuroQoL 5-dimension (EQ-5D) health state is named the EQ-5D-5L profile and is reported as a 5-digit code, with 3125 possible health states based on these remissions. For example, state 11111 indicates no problems in any of the 5 dimensions. This EQ-5D-5L profile will be converted into a weighted health state utility value, named the EQ-5D Index, which is a comparative value of health states by applying a country-specific equation to the profile. The basis for this equation is a set of national estimates derived from the general population, with the benchmark scenario being the United Kingdom (UK) perspective. In cases where the estimate set has not yet been published, the EQ-5D-5L profile will be converted into the EQ-5D Index using the Crosswalk algorithm (van Hout et al., 2012).
[0340] The evaluable population will include the FAS subset with a baseline EQ-5D-5L assessment.
[0341] PGIS
[0342] PGIS data will be presented using summary and descriptive statistics. In addition, PGIS data will be further explored to support anchor-based analysis of clinically meaningful changes and to supplement empirical cumulative distribution functions and probability density function curves.
[0343] PRO-CTCAE
[0344] PRO-CTCAE consists of nominal categories (e.g., from “none” to “very severe” for some items in the questionnaire).
[0345] Calculation or derivation of pharmacokinetic variables
[0346] Population pharmacokinetic and exposure-mitigation / safety analyses
[0347] The nonlinear mixed effects modeling method will be used to develop a population PK model. The impact of physiologically relevant patient characteristics (covariates) and disease on PK will be assessed. The relationship between PK exposure and the effect on safety and efficacy endpoints will be assessed. The results of this analysis will be reported in a separate report. The PK, demographics, safety and efficacy data collected in this study can also be combined with similar data from other studies, and explored using population PK and / or exposure-mitigation / safety analysis.
[0348] Pharmacokinetic analysis
[0349] Due to sparse sampling, non-compartmental analysis will not be performed to calculate PK parameters. Durvalumab serum concentration data and summary statistics will be tabulated. Individual and mean serum concentration-time plots will be generated. Samples below the lower limit of quantitation will be considered missing in the summary statistics.
[0350] Immunogenicity analysis
[0351] Immunogenicity results will be analyzed descriptively summarizing the number and percentage of patients with detectable ADA against durvalumab. For samples that are confirmed positive for the presence of ADA, immunogenicity titers and the presence of neutralizing ADA will be reported. If data permit, the effect of immunogenicity on PK, efficacy, and safety will be evaluated.
[0352] Calculation or derivation of biomarker variables
[0353] Evaluable patients in each cohort will be assessed for PD-L1 status, as defined in secondary objectives.
[0354] Calculation or derivation of pharmacogenetic variables
[0355] For genetic data, only the date on which the patient consented to participate in genetic research and the date on which the blood sample was collected from the patient were recorded in the eCRF and the database.
[0356] Primary endpoint: Overall survival
[0357] OS in FAS will be analyzed by using a stratified log-rank test with adjustment for disease status (initial unresectable or recurrent) and primary tumor location (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer) in IA-2, and a stratified FH(0,1) test in FA. The effect of group A relative to group B will be estimated by HR and its corresponding CI and p-value. Kaplan-Meier plots will be presented by treatment group. A summary of the number and percentage of patients who died, those still in survival follow-up, those lost to follow-up, and those who withdrew consent will be provided together with the mOS for each treatment.
[0358] Cox proportional hazards models will be used to estimate HRs and corresponding CIs based on long-term follow-up OS data. KM plots of overall survival will also be presented by treatment group. Additional analyses may be performed as appropriate.
[0359] Sensitivity analysis
[0360] The assumption of proportionality will be assessed by first examining the complementary log-log (time to event) versus log (time) plots and, if these appear problematic, assessing the extent to which this represents random variation by fitting time-dependent covariates. If lack of proportionality is evident, the variation in treatment effect will be described by presenting segmented HRs calculated over different time periods. In this case, unless there is a large crossover of the survival curves, the HRs can still be meaningfully interpreted as the average HR over time. If lack of proportionality is found, this may be the result of an interaction between treatment and covariates, which will be investigated. In addition, Kaplan-Meier (KM) curves and landmark analyses (e.g., 1-year OS rate) will also help understand the treatment benefit.
[0361] Attrition bias will be investigated by KM censoring time plots using OS data from the primary analysis with the censoring index for the OS analysis reversed.
[0362] Cox proportional hazards modeling will be used to assess the role of covariates on HR estimates. A model incorporating treatment and stratification factors will be constructed to ensure that any output from Cox modeling is likely to be consistent with the results of the stratified log-rank test.
[0363] In addition, we will test for interactions between treatment and stratification factors using the method proposed by Gail and Simon (1985) to rule out any qualitative interactions.
[0364] FA OS will be analyzed using a stratified log-rank test with adjustment for disease status (initial unresectable or recurrent) and primary tumor location (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer) to ensure that any output of the stratified log-rank test is likely to be consistent with the method of the FH(0,1) test.
[0365] A delayed effect, i.e., delayed separation of the survival curves, is expected in immunotherapy trials and has been noted in most IO + chemotherapy versus chemotherapy phase III trials reported to date. The strategy of using the log-rank test in interim analyses and the FH(0,1) test in the final analysis provides robust statistical power and inference across a variety of scenarios, including proportional hazards and delayed effects. The log-rank test is the most powerful method in the proportional hazards scenario, while the FH(0,1) is more powerful in the delayed effect scenario. In addition, in the final analysis, the data maturity was high, so the weighting function of the FH(0,1) test was stable.
[0366] Subgroup analysis
[0367] Subgroup analysis will be performed to compare the OS of Group A vs Group B in the following (but not limited to the following) FAS subgroups:
[0368] Gender (male vs. female)
[0369] Age at randomization (<65 years vs ≥65 years)
[0370] PD-L1 status
[0371] Disease status (initial unresectable vs. recurrent)
[0372] Primary tumor location (intrahepatic cholangiocarcinoma vs extrahepatic cholangiocarcinoma vs gallbladder cancer)
[0373] Race (Asian vs. non-Asian)
[0374] Other baseline variables may also be assessed if there is clinical justification or an imbalance between treatment groups is observed. The goal of subgroup analyses is to assess the consistency of treatment effects across all expected prognostic and / or predictive factors. Forest plots will be presented.
[0375] In addition, for each subgroup, HR (Group A: Group B) and 95% CI will be calculated by Cox proportional hazards model with treatment as the only covariate. These will be presented in forest plots, including HR and 95% CI for the total population.
[0376] Because all of these analyses were to be considered in support of the OS and PFS analyses, no adjustments were made to the significance levels for subgroup testing and sensitivity analyses.
[0377] Progression-free survival
[0378] The secondary PFS analysis will also be based on RECIST 1.1 derived programmatically using investigator tumor assessment. Analysis will be performed using a stratified log-rank test in FAS, adjusted for disease status and primary tumor location. The effect of Arm A relative to Arm B will be estimated by HR and its corresponding 95% CI and p-value.
[0379] Kaplan-Meier plots of PFS will be presented by treatment group. A summary of the number and percentage of patients experiencing a PFS event and the type of event (RECIST 1.1 or death) will be provided along with the median PFS for each treatment.
[0380] Sensitivity analysis
[0381] Sensitivity analyses will be performed to assess possible assessment time bias (which may be introduced if scans are not performed at protocol-specified time points). The midpoint between the time to progression and the previously evaluable RECIST assessment will be analyzed using the log-rank test. For patients whose deaths are treated as PFS events, the date of death will be used to derive the PFS time used in the analysis. This approach has been shown to be robust even in highly asymmetric assessment schedules (Sun and Chen, 2010).
[0382] Attrition bias will be assessed by repeating the PFS analysis but will include the actual PFS event times for patients who had progression or death without progression immediately after 2 or more nonevaluable tumor assessments rather than censoring times. In addition, patients who received subsequent therapy before progression or death will be censored at the last evaluable assessment before receiving subsequent therapy. This analysis will be supported by Kaplan–Meier censoring time plots with the censoring index for the PFS analysis reversed.
[0383] The assumption of proportionality will be assessed by first examining the complementary log-log (time to event) versus log (time) plots and, if these appear problematic, by fitting time-dependent covariates to assess the extent to which this represents random variation. If lack of proportionality is evident, the variation in treatment effect will be described by presenting segmented HRs calculated over different time periods. In this case, unless there is a large crossover of the survival curves, the HRs can still be meaningfully interpreted as the average HR over time. If lack of proportionality is found, this may be the result of an interaction between treatment and covariates, which will be investigated. In addition, Kaplan-Meier curves and landmark analyses (e.g., 1-year PFS rate) will also help understand the treatment benefit.
[0384] Cox proportional hazards modeling will be used to assess the role of covariates on HR estimates. A model incorporating treatment and stratification factors will be constructed to ensure that any output from Cox modeling is likely to be consistent with the results of the stratified log-rank test.
[0385] In addition, we will test for interactions between treatment and stratification factors using the method proposed by Gail and Simon (1985) to rule out any qualitative interactions.
[0386] Further sensitivity analysis can be documented in SAP.
[0387] Subgroup analysis
[0388] Subgroup analyses will be performed to compare PFS between groups A and B in FAS subgroups (according to RECIST 1.1, using investigator assessment).
[0389] Objective response rate
[0390] The ORR will be based on RECIST programmatically derived using investigator tumor data. The ORR between Arm A and Arm B will be compared using a stratified CMH test, adjusting for the same factors as the primary endpoint (disease status and primary tumor location). The results of the analysis will be presented as a p-value. This analysis will be performed on a subset of patients with baseline measurable disease in the FAS.
[0391] A summary will be generated showing the number and percentage of patients with tumor response (CR / PR). The overall visit response data (i.e., FAS) will be listed for all patients. For each treatment group, the best overall response (BoR) will be summarized by n (%) for each category (CR, PR, SD, PD, and NE). No formal statistical analysis of BoR is planned.
[0392] At IA-1, ORR assessments will be repeated according to RECIST 1.1 using tumor data as assessed by BICR in randomized patients who have the opportunity to follow up for at least 32 weeks.
[0393] Duration of remission
[0394] A KM plot of DoR based on RECIST 1.1 investigator assessment will be presented. The median DoR will also be summarized and calculated based on the KM curve. Only patients with confirmed responses will be included in this summary table. A swim lane plot will also be produced that will clearly show the profile of each responding patient.
[0395] At IA-1, DoR assessments will be repeated according to RECIST 1.1 using tumor data as assessed by BICR in randomized patients who have the opportunity to follow up for at least 32 weeks.
[0396] Disease control rate
[0397] DCR according to RECIST 1.1, based on investigator assessment, DCR-24w, and DCR-32w will be summarized for each treatment group (ie, number of patients [%).
[0398] Patient-Reported Outcomes
[0399] EORTC QLQ-C30
[0400] The primary assessment of symptoms, effects, and HRQoL will focus on time to deterioration (TTD) and will be analyzed using a stratified log-rank test, as described for the PFS endpoint. Separate analyses will be performed for global health status / QoL, function (physical, role, cognitive, social, and emotional), multiple symptoms (fatigue and pain), and individual items (loss of appetite and insomnia). The effect of durvalumab therapy relative to placebo will be estimated by HR and its corresponding CI and p-value. Kaplan-Meier plots will be presented by treatment group. A summary of the number and percentage of patients who experienced an event and those who were censored will be provided along with the median for each treatment.
[0401] Additional analyses of HRQoL, impact, and symptoms will focus on comparing mean changes from baseline in global health status / QoL, functioning (physical, role, cognitive, social, and emotional), multiple symptom (fatigue and pain), and single item (appetite loss and insomnia) scores between treatment groups. The analysis population for mean change in HRQoL, impact, or symptom data will be the FAS, and this population will include all randomized patients with an evaluable baseline assessment and at least 1 evaluable post-baseline assessment. A mixed model repeated measures (MMRM) analysis will be performed on all post-baseline scores for each visit, and changes from baseline will be derived. The model includes treatment, visit, and visit-treatment interaction as explanatory variables, and includes baseline score as a covariate. The adjusted mean change from baseline estimate and corresponding 95% CI for each treatment group will be presented together with the overall estimate of the treatment difference, 95% CI, and p-value.
[0402] A summary table of visit remission for each EORTC QLQ-C30 scale / item score (global health status / QoL, 5 functions, and all symptoms) and each visit (improvement, deterioration, and no change) will be presented by treatment group. In addition, a summary table of best global remission will be provided by treatment group for the following domains: global health status / QoL, function (physical, role, cognitive, social, and emotional), multiple symptoms (fatigue and pain), and individual items (loss of appetite and insomnia). Symptom incidence, impact, and QoL / function improvement based on best global remission will be compared between treatment groups using a logistic regression model adjusted for the same factors as the primary endpoint (disease status and primary tumor location). Odds ratios, p-values, and 95% CIs will be presented graphically on forest plots.
[0403] Finally, a summary of the absolute and unadjusted change from baseline value for each EORTC QLQ-C30 scale / item will be reported by visit for each treatment group. Graphical presentations may also be produced as appropriate.
[0404] Additional supportive / exploratory analyses may be performed.
[0405] EORTC QLQ-BIL21
[0406] As described for the EORTC QLQ-C30, the primary assessment for TTD will be the assessment of the single-item symptoms of abdominal pain (item 42), pruritus (item 36), and jaundice (item 35) of the EORTC QLQ-BIL21.
[0407] For TTD of abdominal pain, pruritus, and jaundice, individual items of the EORTC QLQ-BIL21 will be presented using Kaplan-Meier plots along with HRs and corresponding 95% CIs and p-values. A summary of the number and percentage of patients who experienced clinically significant worsening or death in each treatment group and the median TTD will also be provided.
[0408] In addition, the MMRM as described for EORTCQLQ-C30 will be repeated for the EORTC QLQ-BIL21 symptoms of abdominal pain, pruritus, and jaundice to compare mean changes from baseline. All assumptions and outputs as described for EORTC QLQ-C30 apply.
[0409] A summary table of visit remission for each EORTC QLQ-BIL21 scale / item score and each visit (improvement, deterioration, and no change) will be presented by treatment group. In addition, a summary table of best overall remission for abdominal pain, pruritus, and jaundice symptoms will be provided by treatment group. A logistic regression model will be used to compare the incidence of improvement based on best overall remission between treatment groups. Odds ratios, p values, and 95% CI will be presented graphically on forest plots.
[0410] As described for the EORTC QLQ-C30, summaries of the absolute and unadjusted change from baseline value for each EORTC QLQ-BIL21 scale / item will be reported by visit for each treatment group. Graphical presentations may also be produced as appropriate. This descriptive analysis includes item 49 of the EORTC QLQ-BIL21 (“How much are you bothered by the side effects of treatment?”), which assesses patients’ global impression of treatment tolerability, and will thus complement the exploratory findings of the PRO-CTCAE assessment.
[0411] PRO-CTCAE
[0412] PRO-CTCAE data will be presented using summary and descriptive statistics based on the FAS. Descriptive statistics for EORTC QLQ-BIL21 Item 49 (“How much are you bothered by the side effects of treatment?”) will complement the PRO-CTCAE findings. Please refer to the previous section.
[0413] PGIS
[0414] Response to PGIS will be summarized descriptively as the number and corresponding percentage of patients in each category on the questionnaire at each visit by treatment group.
[0415] EQ-5D-5L
[0416] Descriptive statistics will be calculated for each planned visit / time point in the study, for each study group, and in total. This will report the number of patients, the number of EQ-5D questionnaires completed at each visit, and the number and proportion of responses to each dimension of EQ-5D-5L. In addition, summary statistics (e.g., n, mean, median, SD, minimum, and maximum) for the EQ-5D index score and EQ-VAS score will be reported, as well as the change from baseline in the EQ-5D index score and EQ-VAS score.
[0417] Graphs of mean EQ-5D index scores and EQ-VAS scores, including change from baseline, and associated 95% CIs by planned visit / time point in the study may be produced. Additional analyses may be performed to support submissions to payers, and these will be outlined in a separate payer analysis plan.
[0418] Example 2: Global Phase 3 clinical trial of the efficacy of durvalumab combined with chemotherapy in patients with biliary tract cancer (BTC)
[0419] patient
[0420] Adults aged ≥18 years with histologically confirmed unresectable locally advanced or metastatic biliary tract adenocarcinoma (including intrahepatic or extrahepatic cholangiocarcinoma and gallbladder cancer) were eligible. Eligible patients included those with unresectable or metastatic, previously untreated disease at the time of initial diagnosis and those who developed recurrent disease >6 months after curative-intending surgery and >6 months after completion of adjuvant therapy. Additional inclusion criteria included an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, ≥1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, and no prior exposure to immunomodulatory therapy. Patients were excluded if they had ampullary carcinoma, active or previously documented autoimmune or inflammatory disease, or known allergy or hypersensitivity to any study treatment.
[0421] Trial Design and Interventions
[0422] TOPAZ-1 is a phase 3, randomized, double-blind, placebo-controlled, global study. Patients are randomized in a 1:1 ratio to receive durvalumab in combination with gemcitabine and cisplatin or placebo in combination with gemcitabine and cisplatin. Randomization will be stratified by disease status (initial unresectable vs. recurrent) and primary tumor location (intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancer).
[0423] Durvalumab or placebo was administered intravenously in combination with gemcitabine and cisplatin in 21-day cycles for up to 8 cycles. Durvalumab 1500 mg or placebo (administered on day 1 of each cycle) was administered with 1000 mg / m 2 Gemcitabine and 25 mg / m 2 After completion of gemcitabine and cisplatin, durvalumab 1500 mg or placebo monotherapy was administered every 4 weeks until clinical or radiographic (according to RECIST v1.1) disease progression, unacceptable toxicity, withdrawal of consent, or meeting any other discontinuation criteria. Patients who were clinically stable at the time of initial disease progression could continue study treatment at the discretion of the investigator and the patient.
[0424] Evaluate
[0425] Tumor assessments were performed according to RECIST v1.1 using images obtained by computed tomography or magnetic resonance imaging of the chest, abdomen, and pelvis and according to investigator assessment. Adverse events were reported from the time of informed consent until 90 days after the last dose of study treatment; the investigator assessed the causal relationship between reported adverse events and study treatment. Other safety assessments included physical examination, laboratory findings, ECOG performance status, electrocardiogram, and vital signs. Health-related quality of life was assessed with the use of the European Organization for Research and Treatment of Cancer (EORTC)-30-item Core Quality of Life Questionnaire and the EORTC-21-item Cholangiocarcinoma and Gallbladder Cancer Quality of Life Questionnaire. Patient-reported treatment tolerability was assessed with the use of Patient-Reported Outcomes-Common Terminology Criteria for Adverse Events.
[0426] Baseline tumor assessments were performed using images obtained ≤28 days before randomization. During the study, tumor assessments were performed every 6 weeks (±1 week) for the first 24 weeks after randomization and every 8 weeks (±1 week) thereafter until radiographic disease progression, with ≥1 additional follow-up scan. Survival assessments were performed every 2 months after treatment interruption. After data cutoff for the interim analysis, patients who were receiving treatment or in survival follow-up were contacted to provide complete survival data. Tumor biopsy samples newly obtained ≤3 years before screening or archival samples were obtained from all screened patients by image-guided core needle or resection. Tissue samples from all randomized patients were retrospectively assessed for programmed cell death ligand 1 (PD-L1) expression by the Ventana PD-L1 (SP263) immunohistochemistry assay using the positive tumor area (TAP) score. "TAP" is the proportion of tumor and / or immune cells with PD-L1 staining of any intensity and can be used interchangeably with "TIP." A TAP score of ≥1% was defined as tumor cell membranes and / or tumor-associated immune cells with any intensity of PD-L1 staining covering ≥1% of the tumor area. A TAP score of <1% was defined as tumor cell membranes and / or tumor-associated immune cells with any intensity of PD-L1 staining covering <1% of the tumor area. The effect of PD-L1 expression on response and survival outcomes in patients treated with durvalumab and placebo was assessed. Foundation Medicine, Inc. (as described by the U.S. Food and Drug Administration in 2017) used data generated by the FoundationOne assay to analyze tumor tissue samples to confirm MSI status. In brief, principal component analysis was used to analyze the length variability of homopolymer repeat loci within 95 genes, and samples were assigned a qualitative status of MSI high or MSI stable. Samples with low coverage (<250X median) were assigned an MSI unknown status.
[0427] Goals and End Points
[0428] The primary objective was to assess overall survival in the durvalumab group relative to the placebo group, which was defined as the time between randomization and death from any cause. Secondary end points included progression-free survival according to RECIST v1.1, objective response rate, duration of response, and disease control rate and efficacy by PD-L1 expression in the durvalumab group relative to the placebo group using investigator assessment. Progression-free survival was defined as the time from the date of randomization to the date of radiographic disease progression or death as defined by RECIST v1.1. The safety and tolerability of the durvalumab group and the placebo group were assessed. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.
[0429] Statistical analysis
[0430] Efficacy objectives were assessed in the full analysis set that included all randomized patients. The primary analysis of overall survival tested the superiority of the durvalumab regimen over placebo and was analyzed with the use of the log-rank test stratified by disease status (initial unresectable vs. recurrent) and primary tumor location (intrahepatic vs. extrahepatic cholangiocarcinoma vs. gallbladder cancer). This interim analysis was planned to be performed when approximately 397 of the 496 deaths expected at the time of the final analysis had occurred, providing approximately 75% power to detect a significant difference in overall survival at a two-sided significance level of 0.0238, based on the Lan–DeMets approximation of the O'Brien Fleming alpha-spending function boundary. As of the data cutoff date, 424 deaths had occurred, with an actual two-sided significance level of 0.03. Because of the statistically significant improvement in overall survival observed with durvalumab as compared with placebo at the planned interim analysis, the key secondary end point of progression-free survival was formally assessed at this interim analysis. For overall survival and progression-free survival, the effect of durvalumab as compared with placebo was assessed with hazard ratios with 95% confidence intervals and two-sided P values. Progression-free survival was tested with the use of the log-rank test at a two-sided significance level of 0.0481, which was derived on the basis of an alpha-spending function that approximated the Pocock bounds. Multiplicity adjustment for other secondary and exploratory end points was not defined. Therefore, only point estimates and 95% confidence intervals are presented. Confidence intervals for end points other than overall survival and progression-free survival were not adjusted for multiple comparisons and should not be used to infer definitive treatment effects.
[0431] Objective response rates were compared between durvalumab and placebo with the use of the Cochran–Mantel–Haenszel test, stratified by disease status (initial unresectable vs. recurrent) and primary tumor location (intrahepatic vs. extrahepatic cholangiocarcinoma vs. gallbladder cancer). Safety assessments were performed in all patients who received at least one dose of study treatment, and data were summarized with the use of descriptive statistics. All reported confidence intervals were not adjusted for multiplicity and therefore cannot be used to infer effects.
[0432] An independent data monitoring committee reviewed the results of this planned interim analysis and concluded that the data met the pre-specified criteria for a statistically significant difference for the primary objective (overall survival) based on the statistical analysis plan with an acceptable safety profile. Based on this pre-specified interim analysis, the trial achieved statistical significance for the primary objective, so the sponsor was unblinded and the results presented herein will be considered the final formal statistical analysis for overall survival. The TOPAZ-1 study is ongoing, allowing for further exploratory follow-up for overall survival analysis.
[0433] result
[0434] Patients and treatment
[0435] During the study period, 914 patients were enrolled at 105 sites in 17 countries. A total of 685 patients were randomized, of whom 341 were assigned to the durvalumab group and 344 were assigned to the placebo group, and 338 and 342 patients, respectively, received treatment ( Figure 1 ). Patient demographics and disease characteristics were generally balanced between treatment groups (Tables 8 to 10). Table 11 describes the representativeness of trial participants in TOPAZ-1. As of the data cutoff date, the median (95% CI) duration of follow-up was 16.8 (14.8-17.7) months in the durvalumab group and 15.9 (14.9-16.9) months in the placebo group. In addition, 275 (81.4%) patients in the durvalumab group discontinued durvalumab, and 322 (94.2%) patients in the placebo group discontinued placebo. In the full analysis set, the number of patients who received ≥1 subsequent anticancer therapy regimen after interruption was 145 (42.5%) in the durvalumab group and 170 (49.4%) in the placebo group (Table 12).
[0436] Table 8. Patient demographics and baseline characteristics in the full analysis set.
[0437]
[0438]
[0439] *Patients have only locally advanced disease sites.
[0440] Missing status includes MSI unknown or not tested.
[0441] ECOG = Eastern Cooperative Oncology Group; MSI = microsatellite instability; PD-L1 = programmed cell death ligand-1, and TAP = positive tumor area (proportion of tumor and / or immune cells stained with PD-L1 of any intensity).
[0442] Table 9. Patient demographics and baseline characteristics in the full analysis set.
[0443]
[0444]
[0445] *Patients have only locally advanced disease sites.
[0446] Missing status includes MSI unknown or not tested.
[0447] ECOG = Eastern Cooperative Oncology Group; MSI = microsatellite instability; PD-L1 = programmed cell death ligand-1, and TAP = positive tumor area (proportion of tumor and / or immune cells stained with PD-L1 of any intensity).
[0448] Table 10. Extent of baseline disease in the full analysis set.
[0449]
[0450] Data included disease sites occurring at a frequency >5% in either treatment group.
[0451] Table 11. Representativeness of trial participants in TOPAZ-1.
[0452]
[0453]
[0454]
[0455] Table 12. Subsequent anticancer therapy for all treatment groups in the full analysis set.
[0456]
[0457] Data included all patients who discontinued study treatment and received at least one dose of anticancer therapy.
[0458] Main Objectives
[0459] At the time of data cutoff, 198 patients (58.1%) in the durvalumab group and 226 (65.7%) in the placebo group had died. Overall survival was significantly longer with durvalumab versus placebo (hazard ratio, 0.80; 95% CI, 0.66-0.97; P = .021). The median overall survival (95% CI) was 12.8 (11.1-14.0) months in the durvalumab group and 11.5 (10.1-12.5) months in the placebo group ( Figure 4 A).
[0460] The estimated overall survival rates (95% CI) were 54.1% (48.4-59.4) and 48.0% (42.4-53.4) for durvalumab and placebo at 12 months, 35.1% (29.1-41.2) and 25.6% (19.9-31.7) for durvalumab and placebo at 18 months, and 24.9% (17.9-32.5) and 10.4% (4.7-18.8) for durvalumab and placebo at 24 months.
[0461] The Kaplan-Meier curves for overall survival separated after approximately 6 months of treatment, after which there was a clear and persistent separation in favor of the durvalumab group. The hazard ratio (95% CI) for overall survival was 0.91 (0.66-1.26) within 6 months and 0.74 (0.58-0.94) after 6 months. In addition, the kernel smoothed estimate of the hazard function and the associated plots of log-log(time to event) versus log(time) confirmed the departure from the proportional hazards assumption ( Figure 5 ).
[0462] Secondary Objectives
[0463] The median (95% CI) progression-free survival was 7.2 (6.7-7.4) months with durvalumab and 5.7 (5.6-6.7) months with placebo ( Figure 4 B). The hazard ratio for progression-free survival was 0.75 (95% CI, 0.63-0.89; P = 0.001). The investigator-assessed confirmed objective response rate (the sum of the complete response rate and the partial response rate in patients with measurable disease) was 26.7% in the durvalumab group (n = 341) and 18.7% in the placebo group (n = 343) (odds ratio, 1.60; 95% CI, 1.11-2.31). Seven patients (2.1%) and two patients (0.6%) achieved a confirmed complete response with durvalumab and placebo, respectively, and 84 patients (24.6%) and 62 patients (18.1%) achieved a confirmed partial response with durvalumab and placebo, respectively. The percentage of patients with a sustained response of ≥ 9 months was 32.6% in the durvalumab group and 25.3% in the placebo group. The percentage of patients with a sustained response of ≥12 months was 26.1% in the durvalumab group and 15.0% in the placebo group. Tumor responses are summarized in Table 13.
[0464] Table 13. Tumor responses in the full analysis set.
[0465]
[0466]
[0467] Median duration of response (IQR)—months §1.6 (1.3-3.0) 2.7 (1.4-4.1)
[0468] *Assessed by investigator using RECIST v1.1. Analysis of objective response rate was based on patients with measurable disease at baseline in the final analysis set. One patient in the placebo group did not have measurable disease at baseline.
[0469] Best objective response rate of complete response, partial response, and stable disease. Analysis of disease control rate was based on all patients in the full analysis set (durvalumab n=341, placebo n=344).
[0470] Time from first documented response to disease progression, death, or last evaluable RECIST assessment. Analyses of duration of response were based on patients with an objective response and measurable disease at baseline in the full analysis set (durvalumab n=91, placebo n=64).
[0471] §Time from date of randomization to date of first documented response. Analyses of time to response were based on patients in the full analysis set who had an objective response and measurable disease at baseline (durvalumab n=91, placebo n=64).
[0472] IQR=interquartile range, and RECIST v1.1=Response Evaluation Criteria in Solid Tumors version 1.1.
[0473] The overall survival and progression-free survival benefits observed with durvalumab versus gemcitabine and cisplatin were generally consistent across all clinically relevant subgroups analyzed ( Figure 6 A and 6B). In patients with a PD-L1-positive tumor area (TAP) score ≥1% (≥1% of the tumor area occupied by tumor and / or immune cells with any intensity of PD-L1 staining), the hazard ratio for overall survival with durvalumab relative to placebo was 0.79 (95% CI, 0.61-1.00). In patients with a TAP score <1%, the hazard ratio for overall survival with durvalumab relative to placebo was 0.86 (95% CI, 0.60-1.23).
[0474] Security
[0475] The safety analysis set included 680 patients who received ≥1 dose of durvalumab (n=338) or placebo (n=342). The median (range) duration of study treatment was 7.3 (0.1-24.5) months in the durvalumab group and 5.8 (0.2-21.5) months in the placebo group (Table 14).
[0476] Table 14. Treatment Exposures in the Safety Analysis Set.
[0477]
[0478] IQR = interquartile range.
[0479] In the durvalumab group, the median (interquartile range) relative dose intensity of durvalumab, gemcitabine, and cisplatin was 100 (93.8-100), 93.8 (82.5-100), and 93.8 (83.3-100), respectively. In the placebo group, the median (interquartile range) relative dose intensity of placebo, gemcitabine, and cisplatin was 100 (95.0-100), 93.8 (82.2-100), and 93.8 (81.3-100), respectively.
[0480] Adverse events of any grade occurred in 336 (99.4%) patients in the durvalumab group and 338 (98.8%) patients in the placebo group (Table 15). Grade 3 / 4 adverse events occurred in 256 (75.7%) patients in the durvalumab group and 266 (77.8%) patients in the placebo group (Table 15). The rate of discontinuation of any treatment portion due to possible treatment-related adverse events was 8.9% in the durvalumab group and 11.4% in the placebo group (Table 15). The number of deaths due to adverse events was 12 (3.6%) in the durvalumab group and 14 (4.1%) in the placebo group. Deaths caused by treatment-related adverse events occurred in 2 (0.6%) patients in the durvalumab group and 1 (0.3%) patient in the placebo group (Table 15). The most common adverse events were anemia (48.2%), nausea (40.2%), constipation (32.0%), and neutropenia (31.7%) in the durvalumab group and anemia (44.7%), nausea (34.2%), and decreased neutrophil count (31.0%) in the placebo group (Table 16). Grade 3 or 4 treatment-related adverse events occurred in ≥2% of patients in the durvalumab group and the placebo group and are listed in Table 17. The rate of immune-mediated adverse events was 12.7% for durvalumab and 4.7% for placebo. Grade 3 or 4 immune-mediated adverse events occurred in 2.4% of patients in the durvalumab group and 1.5% of patients in the placebo group (Table 18).
[0481] Table 15. Summary of safety data in the safety analysis set.
[0482]
[0483]
[0484] *Treatment-related adverse events leading to death were ischemic stroke and liver failure in the durvalumab group and polymyositis in the placebo group.
[0485] Table 16. Adverse events of any grade with any causality that occurred in ≥10% of either treatment group or Grade 3 or 4 that occurred in ≥2% of either treatment group in the safety analysis set.
[0486]
[0487]
[0488] Table 17. Grade 3 or 4 treatment-related adverse events occurring in ≥2% of patients in either treatment group in the safety analysis set.
[0489]
[0490]
[0491] Table 18. Immune-mediated adverse events in the safety analysis population.
[0492]
[0493] *Immune-mediated adverse events are defined as events that are related to drug exposure and
[0494] This is consistent with an immune-mediated mechanism of action, and there is no clear alternative etiology.
[0495] Events in the “other rare conditions / miscellaneous” category were immune-mediated arthritis in the durvalumab group and arthritis in the placebo group.
[0496] Durvalumab plus gemcitabine and cisplatin demonstrated a statistically significant prolongation of overall survival as compared with placebo plus gemcitabine and cisplatin in previously untreated advanced biliary tract cancer. The large, international patient population in TOPAZ-1 was representative of the general population of patients with advanced biliary tract cancer, and characteristics were well balanced between treatment groups. The addition of durvalumab to chemotherapy benefited patients whose tumors had both PD-L1 TAP ≥ 1% and TAP < 1%, confirming that PD-L1 status has limited value in predicting clinical benefit with durvalumab plus chemotherapy in this patient population. The addition of durvalumab to chemotherapy was safe, and the toxicities observed were similar to those commonly seen with chemotherapy or immunotherapy alone. In this double-blind trial, durvalumab did not add additional toxicities to those observed with chemotherapy, and the incidence of grade 3 or 4 treatment-related adverse events was very similar between treatment groups. The Phase 3 TOPAZ-1 trial achieved its primary objective of improving overall survival with durvalumab and chemotherapy at a preplanned interim analysis while demonstrating a manageable safety profile. Our global Phase 3 trial showed that immunotherapy provided a statistically significant improvement in median overall survival in advanced biliary tract cancer.
[0497] References
[0498] Aaronson et al., "The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology," J. Natl. Cancer Inst. 85(5): 365-76 (1993).
[0499] Basch et al., "Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes," J. Natl. Cancer Inst. 101(23): 1624-32 (2009).
[0500] Boilève et al., "Immunotherapy in Advanced Biliary Tract Cancers," Cancers (Basel) 13(7): 1569 (2021).
[0501] Bridgewater et al., "Biliary tract cancer: Epidemiology, radiotherapy, and molecular profiling," Am. Soc. Clin. Oncol. Educ. Book 35: e194-203 (2016).
[0502] Brindley et al., "Cholangiocarcinoma," Nat. Rev. Dis. Primers 7(1): 65 (2021).
[0503] European Medicines Agency,"Guideline on the evaluation of anticancermedicinal products in man,"2012(accessed at www.ema.europa.eu / docs / en_GB / document_library / Scientific_guideline / 2013 / 01 / WC500137128.pdf).
[0504] EuroQol Group,"EQ-5D-5L user guide:Basic information on how to usethe EQ-5D-5L instrument,version 2.1,April 2015,"2015(accessed June 8,2018ateuroqol.org / wp-content / uploads / 2016 / 09 / EQ-5D-5L_UserGuide_2015.pdf).
[0505] Fayers et al.,"EORTC QLQ-C30 Scoring Manual"(3rd Edition2001).
[0506] FDA-NIH Biomarker Working Group,"BEST(Biomarkers,EndpointS,and otherTools)Resource"(Silver Spring(MD):Food and Drug Administration(US),2016)(accessed at www.ncbi.nlm.nih.gov / books / NBK338448).
[0507] Fife and Bluestone,"Control of peripheral T-cell tolerance andautoimmunity via the CTLA-4and PD-1pathways,"Immunol.Rev.224:166-82(2008).
[0508] Fiteni et al.,"Cisplatin / gemcitabine or oxaliplatin / gemcitabine inthe treatment of advanced biliary tract cancer:a systematic review,"CancerMed.3(6):1502-11(2014).
[0509] Friend et al.,"Development of a questionnaire(EORTC module)to measurequality of life in patients with cholangiocarcinoma and gallbladder cancer,the EORTC QLQ-BIL21,"Br.J.Cancer 104(4):587-92(2011).
[0510] Gail and Simon,"Tests for qualitative interactions between treatmenteffects and patient subsets,"Biometrics 41(2):361-72(1985).
[0511] Glimm et al.,"Hierarchical testing of multiple endpoints in group-sequential trials,"Stat.Med.29(2):219-28(2010).
[0512] Kaup-Robberts et al.,"Validation of the EORTC QLQ-BIL-21questionnairefor measuring quality of life in patients with cholangiocarcinoma and cancerofthe gallbladder,"Br.J.Cancer 115(9):1032-38(2016).
[0513] Kim et al.,"Incidence and overall survival ofbiliary tract cancers inSouth Korea from 2006 to 2015:Using the National Health InformationDatabase,"GutLiver 13(1):104-13(2019).
[0514] Kluetz et al.,"Incorporating the patient experience into regulatorydecision making in the USA,Europe,and Canada,"Lancet Oncol.19(5):e267-74(2018).
[0515] Lan and DeMets,"Discrete sequential boundaries for clinical trials,"Biometrika 70:659-63(1983).
[0516] Lee et al.,"Gemcitabine and oxaliplatin with or without erlotinib inadvanced biliary-tract cancer:A multicentre,open-label,randomised,phase 3study,"Lancet Oncol.13(2):181-88(2012).
[0517] Leone et al.,"Panitumumab in combination with gemcitabine andoxaliplatin does not prolong survival in wild-type KRAS advanced biliarytract cancer:A randomized phase 2 trial(Vecti-BIL study),"Cancer122(4):574-81(2016).
[0518] Litwin et al.,"Differences in urologist and patient assessments ofhealth related quality of life in men with prostate cancer:Results of theCaPSURE database,"J.Urol.159:1988-92(1998).
[0519] Malka et al.,"Gemcitabine and oxaliplatin with or without cetuximabin advanced biliary-tract cancer(BINGO):A randomised,open-label,non-comparative phase 2 trial,"Lancet Oncol.15(8):819-28(2014).
[0520] Okusaka et al.,"Gemcitabine alone or in combination with cisplatin inpatients with biliary tract cancer:A comparative multicentre study in Japan,"Br.J.Cancer 103(4):469-74(2010).
[0521] Osoba et al.,"Interpreting the significance of changes in health-related quality-of-life scores,"J.Clin.Oncol.16(1):139-44(1998).
[0522] Sprangers and Aaronson,"The role of health care providers andsignificant others in evaluating the quality oflife ofpatients with chronicdisease:A review,"J.Clin.Epidemiol.45:743-60(1992).
[0523] Sun and Chen,"Comparison of Finkelstein's Method with theconventional approach for interval-censored data analysis,"Stat.Biopharm.Res.2(1):97-108(2010).
[0524] Torre et al.,"Worldwide burden of and trends in mortality fromgallbladder and other biliary tract cancers,"Clin.Gastroenterol.Hepatol.16(3):427-37(2018).
[0525] Trask et al.,"Patient-Reported Outcomes version of the CommonTerminology Criteria for Adverse Events:Methods for item selection inindustry sponsored oncology clinical trials,"Clin.Trials 15(6):616-23(2018).
[0526] Tsiatis,"Repeated significance testing for a general classofstatistics used in censored survival analysis,"J.Am.Stat.Assoc.380:855-61(1982).
[0527] U.S.Food and Drug Administration,"Guidance for Industry,ClinicalTrial Endpoints for the Approval of Cancer Drugs and Biologics 2007,"2007(accessed at www.fda.gov / downloads / Drugs / Guidances / ucm071590.pdf).
[0528] U.S.Food and Drug Administration,"Summary of safety and effectivenessdata,"2017(accessed February 7,2022,at www.accessdata.fda.gov / cdrh_docs / pdf17 / P170019B.pdf).
[0529] Valle et al.,"Cisplatin plus gemcitabine versus gemcitabine forbiliary tract cancer,"N.Engl.J.Med.362(14):1273-81(2010).
[0530] Valle et al.,"Cediranib or placebo in combination with cisplatin andgemcitabine chemotherapy for patients with advanced biliary tract cancer(ABC-03):A randomised phase 2 trial,"Lancet Oncol.16(8):967-78(2015).
[0531] Valle et al.,"Biliary tract cancer,"Lancet 397(10272):428-44(2021).
[0532] Valle et al.,"Addition of ramucirumab or merestinib to standardfirst-line chemotherapy for locally advanced or metastatic biliary tractcancer:A randomised,double-blind,multicentre,phase 2 study,"Lancet Oncol.22(10):1468-82(2021).
[0533] Van Dyke et al., "Biliary tract cancer incidence and trends in the United States by demographic group,1999-2013," Cancer 125(9):1489-98(2019).
[0534] van Hout et al., "Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets," Value Health 15(5):708-15(2012).
[0535] Wang et al., "The world-wide incidence of biliary tract cancer (BTC)," J.Clin.Oncol.38(Suppl 4):585(2020).
[0536] Yachida et al., "Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma," Cancer Cell 29:229-40 (2016).
[0537] Example:
[0538] Example 1: A method of treating a patient with biliary tract cancer (BTC), the method comprising treating the patient with an anti-PD-L1 antibody and chemotherapy.
[0539] Example 2: A method for increasing the overall survival of a patient with biliary tract cancer (BTC), the method comprising treating the patient with an anti-PD-L1 antibody and chemotherapy.
[0540] Example 3: A method for prolonging progression-free survival in a patient with biliary tract cancer (BTC), the method comprising treating the patient with an anti-PD-L1 antibody and chemotherapy.
[0541] Example 4: A combination of an anti-PD-L1 antibody and chemotherapy for use in the treatment of biliary tract cancer (BTC).
[0542] Example 5: A combination of an anti-PD-L1 antibody and chemotherapy for use in treating biliary tract cancer (BTC) in a patient, wherein the patient's overall survival is increased.
[0543] Example 6: A combination of an anti-PD-L1 antibody and chemotherapy for use in treating biliary tract cancer (BTC) in a patient, wherein the patient has an extended progression-free survival.
[0544] Example 7: Use of an anti-PD-L1 antibody in combination with chemotherapy in the manufacture of a medicament for use in the treatment of biliary tract cancer (BTC).
[0545] Example 8: Use of an anti-PD-L1 antibody in combination with chemotherapy in the manufacture of a medicament for use in treating biliary tract cancer (BTC) in a patient, wherein the patient's overall survival is increased.
[0546] Example 9: Use of an anti-PD-L1 antibody in combination with chemotherapy in the manufacture of a medicament for use in treating biliary tract cancer (BTC) in a patient, wherein the patient has an extended progression-free survival.
[0547] Embodiment 10: The method, combination for use, or use according to any one of embodiments 1-9, wherein the chemotherapy comprises concurrent chemotherapy.
[0548] Embodiment 11: The method, combination for use, or use according to any one of embodiments 1-10, wherein the chemotherapy comprises platinum-based chemotherapy and / or antimetabolite-based chemotherapy.
[0549] Embodiment 12: The method, combination for use, or use according to Embodiment 11, wherein the platinum-based chemotherapy is cisplatin or carboplatin.
[0550] Embodiment 13: The method, combination for use, or use according to Embodiment 11 or Embodiment 12, wherein the antimetabolite-based chemotherapy is gemcitabine.
[0551] Embodiment 14: The method, combination for use, or use according to any one of Embodiments 1-13, wherein the anti-PD-L1 antibody is durvalumab, avelumab, or atezolizumab.
[0552] Embodiment 15: The method, combination for use, or use according to any one of Embodiments 1-14, wherein the anti-PD-L1 antibody and / or chemotherapy is administered intravenously.
[0553] Embodiment 16: The method, combination for use, or use according to any one of Embodiments 1-15, wherein the anti-PD-L1 antibody is administered to the patient once every three weeks (Q3W).
[0554] Embodiment 17: The method, combination for use, or use according to any one of Embodiments 1-16, wherein the doses of the anti-PD-L1 antibody and chemotherapy are administered concurrently or sequentially.
[0555] Embodiment 18: The method, combination for use, or use according to any one of Embodiments 1-17, wherein the second dose of chemotherapy is administered 7 days after the first dose of chemotherapy.
[0556] Embodiment 19: The method, combination for use, or use according to any one of embodiments 1-18, comprising a treatment cycle lasting 21 days, wherein:
[0557] (a) the first dose of the anti-PD-L1 antibody and the chemotherapy is administered on day 1 of the treatment cycle, and
[0558] (b) The second dose of chemotherapy is administered on Day 8 of the treatment cycle.
[0559] Embodiment 20: The method, combination for use, or use according to Embodiment 19, wherein the treatment cycle is repeated 1, 2, 3, 4, 5, 6, 7, or 8 times.
[0560] Embodiment 21: The method, combination for use, or use according to any one of Embodiments 1-20, wherein the anti-PD-L1 antibody is administered after completion of treatment with chemotherapy.
[0561] Embodiment 22: The method, combination for use, or use according to any one of Embodiments 19-21, wherein the anti-PD-L1 antibody is administered after the final treatment cycle is completed.
[0562] Embodiment 23: The method, combination for use, or use according to Embodiment 22, wherein the anti-PD-L1 antibody is administered once every four weeks (Q4W).
[0563] Embodiment 24: The method, combination for use, or use according to any one of Embodiments 1-23, wherein treatment with the human anti-PD-L1 antibody comprises administering 1000-2000 mg of the anti-PD-L1 antibody.
[0564] Embodiment 25: The method, combination for use, or use according to Embodiment 24, wherein treatment with the human anti-PD-L1 antibody comprises administering 1500 mg of the anti-PD-L1 antibody.
[0565] Embodiment 26: The method, combination for use, or use according to any one of Embodiments 1-25, wherein the treatment with chemotherapy comprises administering 1000 mg / m2 Gemcitabine and 25 mg / m 2 of cisplatin.
[0566] Embodiment 27: The method, combination for use, or use according to any one of Embodiments 1-26, wherein the biliary tract cancer is unresectable, locally advanced, or metastatic.
[0567] Embodiment 28: The method, combination for use, or use according to any one of embodiments 1-27, wherein the patient has not been previously treated for BTC.
[0568] Embodiment 29: The method, combination for use, or use according to any one of Embodiments 1-28, wherein the patient develops recurrent disease more than 6 months after cure-intending surgery, or more than 6 months after completion of adjuvant therapy.
[0569] Embodiment 30: The method, combination for use, or use according to any one of embodiments 1-29, wherein the toxicity observed is similar to that typically seen with chemotherapy or immunotherapy alone.
Claims
1. A method for increasing the overall survival of a patient with biliary tract cancer (BTC), the method comprising treating the patient with an anti-PD-L1 antibody and chemotherapy.
2. The method of claim 1, wherein the chemotherapy comprises concurrent chemotherapy.
3. The method of claim 1 or claim 2, wherein the chemotherapy comprises platinum-based chemotherapy and / or antimetabolite-based chemotherapy.
4. The method of claim 3, wherein the platinum-based chemotherapy is cisplatin or carboplatin.
5. The method of claim 3, wherein the antimetabolite-based chemotherapy is gemcitabine.
6. The method of any one of claims 1-5, wherein the anti-PD-L1 antibody is durvalumab, avelumab, sugemalimab, or atezolizumab.
7. The method of any one of claims 1-6, wherein the anti-PD-L1 antibody and / or chemotherapy is administered intravenously.
8. The method of any one of claims 1-7, wherein the anti-PD-L1 antibody is administered to the patient once every three weeks (Q3W).
9. The method of any one of claims 1-8, wherein doses of the anti-PD-L1 antibody and chemotherapy are administered concurrently or sequentially.
10. The method of any one of claims 1-9, wherein the second dose of chemotherapy is administered 7 days after the first dose of chemotherapy.
11. The method of any one of claims 1-10, comprising a treatment cycle lasting 21 days, wherein: (a) the first dose of the anti-PD-L1 antibody and the chemotherapy is administered on day 1 of the treatment cycle, and (b) The second dose of chemotherapy is administered on Day 8 of the treatment cycle.
12. The method of claim 11, wherein the treatment cycle is repeated 1, 2, 3, 4, 5, 6, 7, or 8 times.
13. The method of any one of claims 1-12, wherein the anti-PD-L1 antibody is administered after completion of treatment with chemotherapy.
14. The method of any one of claims 11-13, wherein the anti-PD-L1 antibody is administered after the final treatment cycle is completed.
15. The method of claim 14, wherein the anti-PD-L1 antibody is administered once every four weeks (Q4W).
16. The method of any one of claims 1-15, wherein treatment with a human anti-PD-L1 antibody comprises administering 1000-2000 mg of the anti-PD-L1 antibody.
17. The method of claim 16, wherein treating with a human anti-PD-L1 antibody comprises administering 1500 mg of the anti-PD-L1 antibody.
18. The method of any one of claims 1-17, wherein treating with chemotherapy comprises administering 1000 mg / m 2 Gemcitabine and 25 mg / m 2 of cisplatin.
19. The method of any one of claims 1-18, wherein the biliary tract cancer is unresectable, locally advanced, or metastatic.
20. The method of any one of claims 1-19, wherein the patient has not been previously treated for BTC.
21. The method of any one of claims 1-20, wherein the patient develops recurrent disease more than 6 months after cure-intending surgery, or more than 6 months after completion of adjuvant therapy.
22. The method of any one of claims 1-21, wherein the toxicity observed is similar to that typically seen with chemotherapy or immunotherapy alone.
23. A method for extending progression-free survival in a patient with biliary tract cancer (BTC), the method comprising treating the patient with an anti-PD-L1 antibody and chemotherapy.
24. The method of claim 23, wherein the chemotherapy comprises concurrent chemotherapy.
25. The method of claim 23 or claim 24, wherein the chemotherapy comprises platinum-based chemotherapy and / or antimetabolite-based chemotherapy.
26. The method of claim 25, wherein the platinum-based chemotherapy is cisplatin or carboplatin.
27. The method of claim 25, wherein the antimetabolite-based chemotherapy is gemcitabine.
28. The method of any one of claims 23-27, wherein the anti-PD-L1 antibody is durvalumab, avelumab, sugemalimab, or atezolizumab.
29. The method of any one of claims 23-28, wherein the anti-PD-L1 antibody and / or chemotherapy is administered intravenously.
30. The method of any one of claims 23-29, wherein the anti-PD-L1 antibody is administered to the patient once every three weeks (Q3W).
31. The method of any one of claims 23-30, wherein doses of the anti-PD-L1 antibody and chemotherapy are administered concurrently or sequentially.
32. The method of any one of claims 23-31, wherein the second dose of chemotherapy is administered 7 days after the first dose of chemotherapy.
33. The method of any one of claims 23-32, comprising a treatment cycle lasting 21 days, wherein: (a) the first dose of the anti-PD-L1 antibody and the chemotherapy is administered on day 1 of the treatment cycle, and (b) The second dose of chemotherapy is administered on Day 8 of the treatment cycle.
34. The method of claim 11, wherein the treatment cycle is repeated 1, 2, 3, 4, 5, 6, 7, or 8 times.
35. The method of any one of claims 23-33, wherein the anti-PD-L1 antibody is administered after completion of treatment with chemotherapy.
36. The method of any one of claims 23-35, wherein the anti-PD-L1 antibody is administered after the final treatment cycle is completed.
37. The method of claim 36, wherein the anti-PD-L1 antibody is administered once every four weeks (Q4W).
38. The method of any one of claims 32-37, wherein treatment with a human anti-PD-L1 antibody comprises administering 1000-2000 mg of the anti-PD-L1 antibody.
39. The method of claim 38, wherein treating with a human anti-PD-L1 antibody comprises administering 1500 mg of the anti-PD-L1 antibody.
40. The method of any one of claims 23-39, wherein treating with chemotherapy comprises administering 1000 mg / m 2 Gemcitabine and 25 mg / m 2 of cisplatin.
41. The method of any one of claims 23-40, wherein the biliary tract cancer is unresectable, locally advanced, or metastatic.
42. The method of any one of claims 23-41, wherein the patient has not been previously treated for BTC.
43. The method of any one of claims 23-42, wherein the patient develops recurrent disease more than 6 months after cure-intending surgery, or more than 6 months after completion of adjuvant therapy.
44. The method of any one of claims 23-43, wherein the toxicity observed is similar to that typically seen with chemotherapy or immunotherapy alone.
45. A method of treating a patient with biliary tract cancer (BTC), the method comprising treating the patient with an anti-PD-L1 antibody and chemotherapy.
46. The method of claim 45, wherein the chemotherapy comprises concurrent chemotherapy.
47. The method of claim 45 or claim 46, wherein the chemotherapy comprises platinum-based chemotherapy and / or antimetabolite-based chemotherapy.
48. The method of claim 47, wherein the platinum-based chemotherapy is cisplatin or carboplatin.
49. The method of claim 47, wherein the antimetabolite-based chemotherapy is gemcitabine.
50. The method of any one of claims 45-49, wherein the anti-PD-L1 antibody is durvalumab, avelumab, sugemalimab, or atezolizumab.
51. The method of any one of claims 45-50, wherein the anti-PD-L1 antibody and / or chemotherapy is administered intravenously.
52. The method of any one of claims 45-51, wherein the anti-PD-L1 antibody is administered to the patient once every three weeks (Q3W).
53. The method of any one of claims 45-52, wherein doses of the anti-PD-L1 antibody and chemotherapy are administered concurrently or sequentially.
54. The method of any one of claims 45-53, wherein the second dose of chemotherapy is administered 7 days after the first dose of chemotherapy.
55. The method of any one of claims 45-54, comprising a treatment cycle lasting 21 days, wherein: (a) the first dose of the anti-PD-L1 antibody and the chemotherapy is administered on day 1 of the treatment cycle; and (b) The second dose of chemotherapy is administered on Day 8 of the treatment cycle.
56. The method of claim 55, wherein the treatment cycle is repeated 1, 2, 3, 4, 5, 6, 7, or 8 times.
57. The method of any one of claims 45-56, wherein the anti-PD-L1 antibody is administered after completion of treatment with chemotherapy.
58. The method of any one of claims 45-57, wherein the anti-PD-L1 antibody is administered after the final treatment cycle is completed.
59. The method of claim 58, wherein the anti-PD-L1 antibody is administered once every four weeks (Q4W).
60. The method of any one of claims 45-59, wherein treatment with a human anti-PD-L1 antibody comprises administering 1000-2000 mg of the anti-PD-L1 antibody.
61. The method of claim 60, wherein treatment with a human anti-PD-L1 antibody comprises administering 1500 mg of the anti-PD-L1 antibody.
62. The method of any one of claims 45-61, wherein treating with chemotherapy comprises administering 1000 mg / m 2 Gemcitabine and 25 mg / m 2 of cisplatin.
63. The method of any one of claims 45-62, wherein the biliary tract cancer is unresectable, locally advanced, or metastatic.
64. The method of any one of claims 45-63, wherein the patient has not been previously treated for BTC.
65. The method of any one of claims 45-64, wherein the patient develops recurrent disease more than 6 months after cure-intending surgery, or more than 6 months after completion of adjuvant therapy.
66. The method of any one of claims 45-65, wherein the toxicity observed is similar to that typically seen with chemotherapy or immunotherapy alone.
67. A combination of an anti-PD-L1 antibody and chemotherapy for use in the treatment of biliary tract cancer (BTC).
68. A combination of an anti-PD-L1 antibody and chemotherapy for use in treating biliary tract cancer (BTC) in a patient, wherein the patient's overall survival is increased.
69. A combination of an anti-PD-L1 antibody and chemotherapy for use in a method of increasing overall survival in patients with biliary tract cancer (BTC).
70. A combination of an anti-PD-L1 antibody and chemotherapy for use in treating biliary tract cancer (BTC) in a patient, wherein the patient has an increased progression-free survival.
71. An anti-PD-L1 antibody in combination with chemotherapy for use in a method of prolonging progression-free survival in patients with biliary tract cancer (BTC).
72. Use of an anti-PD-L1 antibody in combination with chemotherapy in the manufacture of a medicament for use in the treatment of biliary tract cancer (BTC).
73. Use of an anti-PD-L1 antibody in combination with chemotherapy in the manufacture of a medicament for use in a method of increasing overall survival in patients with biliary tract cancer (BTC).
74. Use of an anti-PD-L1 antibody in combination with chemotherapy in the manufacture of a medicament for use in a method of prolonging progression-free survival in patients with biliary tract cancer (BTC).
